

REVIEW

Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review

MO Trépanier¹, KE Hopperton¹, R Mizrahi^{2,3,4}, N Mechawar^{5,6} and RP Bazinet¹

Schizophrenia is a psychiatric disorder which has a lifetime prevalence of ~1%. Multiple candidate mechanisms have been proposed in the pathogenesis of schizophrenia. One such mechanism is the involvement of neuroinflammation. Clinical studies, including neuroimaging, peripheral biomarkers and randomized control trials, have suggested the presence of neuroinflammation in schizophrenia. Many studies have also measured markers of neuroinflammation in postmortem brain samples from schizophrenia patients. The objective of this study was to conduct a systematic search of the literature on neuroinflammation in postmortem brains of schizophrenia patients indexed in MEDLINE, Embase and PsycINFO. Databases were searched up until 20th March 2016 for articles published on postmortem brains in schizophrenia evaluating microglia, astrocytes, glia, cytokines, the arachidonic cascade, substance P and other markers of neuroinflammation. Two independent reviewers extracted the data. Out of 5385 articles yielded by the search, 119 articles were identified that measured neuroinflammatory markers in schizophrenic postmortem brains. Glial fibrillary acidic protein expression was elevated, lower or unchanged in 6, 6 and 21 studies, respectively, and similar results were obtained for glial cell densities. On the other hand, microglial markers were increased, lower or unchanged in schizophrenia in 11, 3 and 8 studies, respectively. Results were variable across all other markers, but SERPINA3 and IFITM were consistently increased in 4 and 5 studies, respectively. Despite the variability, some studies evaluating neuroinflammation in postmortem brains in schizophrenia suggest an increase in microglial activity and other markers such as SERPINA3 and IFITM. Variability across studies is partially explained by multiple factors including brain region evaluated, source of the brain, diagnosis, age at time of death, age of onset and the presence of suicide victims in the cohort.

Molecular Psychiatry (2016) **21**, 1009–1026; doi:10.1038/mp.2016.90; published online 7 June 2016

INTRODUCTION

Schizophrenia is a psychiatric disorder which affects ~0.5 to 1% of the population in their lifetime.^{1,2} Psychosis normally arises in the late teenage years or early adulthood, between 18 and 25 years of age.³ Although the cause underlying this mental illness remains to be elucidated, several biological factors have been proposed, including abnormalities in oligodendrocytes,^{4,5} N-methyl-D-aspartate (NMDA) signaling⁶ and dopaminergic transmission.⁷

Neuroinflammation has been suggested to be a potential contributor in the pathogenesis of the schizophrenia.^{8–11} Classically, the brain is considered to be immunologically privileged due to the blood–brain barrier limiting cell entry.¹² Under normal conditions, microglia, the resident immune cells of the brain, are found in a ramified ('resting') state, surveying the environment. Following injury or the exposure to pro-inflammatory signals such as interferon (IFN)- γ and tumor necrosis factor (TNF)- α , ramified microglia can become activated and release pro-inflammatory cytokines such as interleukin (IL)-1 β , IL-6, IFN- γ or chemokine (c-x-c motif) ligand (CCL) 11.¹³ Microglia also increase the expression of cyclooxygenase (COX)-2, an enzyme involved in the arachidonic cascade, which can lead to the production of the pro-inflammatory lipid mediator prostaglandin E₂.¹⁴ Pro-inflammatory cytokines released from microglia, such as IL-1 β ,

can activate astrocytes. In turn, activated astrocytes also have the ability to release pro-inflammatory cytokines and chemokines, such as IL-1 β , CCL5 and TNF- α ,¹⁵ and typically display increased glial fibrillary acidic protein (GFAP) expression.¹⁶

Evidence has accumulated supporting a link between inflammation and schizophrenia. Serum or plasma concentrations of pro-inflammatory markers have been investigated in several studies. Two meta-analyses illustrate that IL-6 is consistently elevated in serum and plasma of patients with schizophrenia,^{17,18} whereas IL-1 β and TNF- α were found to be increased in one meta-analysis,¹⁸ but not in the other.¹⁷ Genetic studies have also linked polymorphisms in major histocompatibility complex (MHC) regions with risk of schizophrenia.^{19,20}

Neuroinflammation has also been associated with schizophrenia. Advancements in *in vivo* PET imaging has enabled imaging of neuroinflammation in schizophrenic patients.²¹ However, studies imaging the translocator protein 18 kDa (TSPO), a marker of activated microglia, have yielded mixed results. Early studies utilizing the TSPO ligand [¹¹C]PK11195 suggested that schizophrenic patients have higher levels of activated microglia compared with healthy controls.^{22,23} More recent studies, using second-generation TSPO ligands, however, had mixed results, with some reporting increased microglia activation in schizophrenia,²⁴

¹Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; ²Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada; ³Institute of Medical Science, University of Toronto, Toronto, ON, Canada; ⁴Department of Psychiatry, University of Toronto, Toronto, ON, Canada; ⁵McGill Group for Suicide Studies, Douglas Mental Health University Institute, Montreal, QC, Canada and ⁶Department of Psychiatry, McGill University, Montreal, QC, Canada. Correspondence: Dr, Associate Professor RP Bazinet, Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, FitzGerald Building, 150 College St., Room 306, Toronto, ON M5S 3E2, Canada.

E-mail: richard.bazinet@utoronto.ca

Received 7 January 2016; revised 29 March 2016; accepted 20 April 2016; published online 7 June 2016

whereas others failed to replicate earlier studies and found no difference between patients and healthy controls.^{25,26} The reasons for the disparities between studies are not clear, but likely related to different TSPO ligands used or different samples studied across research groups.

As schizophrenia has been associated with inflammation, attempts have been made to treat symptoms with non-steroidal anti-inflammatory drugs (NSAID) as an add-on therapy to conventional treatments. Although some studies found added benefits of NSAID on symptoms,^{27–29} one study did not show any beneficial effects.³⁰ A meta-analysis of five published and three non-published studies found no effect of NSAID on the Positive and Negative Syndrome Scale total scores, but did detect a small yet statistically significant beneficial effect of NSAID add-on therapy for the treatment of positive symptoms.³¹ Omega-3 polyunsaturated fatty acids (n-3 PUFA), which are also thought to have anti-neuroinflammatory properties,^{32,33} have also yielded mixed results in the treatment of schizophrenia. Administration of 3 g per day of n-3 PUFA in combination with 300 mg per day of alpha-lipoic acid for up to 2 years did not decrease the relapse rate of schizophrenic patients.³⁴ An earlier report, however, found that administration of n-3 PUFA was beneficial in reducing the conversion of subthreshold psychosis to a first episode psychotic event in adolescents.³⁵

It is unclear whether neuroinflammation associated with schizophrenia is causing or is a result of the disorder. It has been suggested that microglia activation and cytokine release could lead to neuronal and glial injury,³⁶ resulting in dopaminergic and glutamatergic system dysregulation.^{37,38} Neurogenesis and synapse connectivity may also be affected by neuroinflammation.^{39,40} Moreover, activation of astrocytes may also cause abnormal production of kynurenic acid and upregulate the expression of glutamate transporters.^{9,11,41}

Despite the mixed results in both *in vivo* imaging and clinical trials, it appears plausible that inflammation may have a role in schizophrenia. Numerous postmortem studies have measured pro-inflammatory markers in patients suffering from schizophrenia. To date, no systematic review of the field has been published on the topic. This article set out to systematically characterize the literature on neuroinflammation as measured in postmortem brains from schizophrenia patients.

MATERIALS AND METHODS

We performed a systematic search for literature indexed in MEDLINE, Embase and PsycINFO up to 20th March 2016. Full search criteria can be found in the Supplementary Materials.

Only peer-reviewed primary research articles were considered as eligible studies. References of yielded articles were searched for possible eligible articles that were missed by the search.

Once duplicate articles were removed, studies were screened based on title and abstract for several components including studies which were on schizophrenia and (1) carried out with postmortem brain samples, (2) measured neuroinflammatory markers and (3) were compared with matched psychiatrically and neurologically healthy controls. Studies evaluating markers of astroglia, microglia, gliosis, cytokines, arachidonic acid cascade and substance P were included (for full search terms, see Supplementary Materials). Other markers were considered if the authors referred to their implication in neuroinflammation. Although not always stated by the authors as a microglial marker, MHC (also known as human leukocyte antigen, HLA) complex I and II were both considered as possible microglial markers as both have been shown to be elevated in microglia.⁴² Untargeted approaches, such as microarray and shotgun proteomics, were also excluded unless targeted approaches were used to confirm the results. Viruses and infection were not considered for this review and were excluded. Reviews were searched for relevant articles, but themselves were excluded from the results. Finally, non-English papers and conference abstracts were also excluded.

Articles were evaluated and data were extracted onto an electronic data extraction form by MOT. Extractions were confirmed by a second independent reviewer (KEH). From eligible studies, number of subjects, sex, race, duration of illness, onset of illness, postmortem interval, freezer time, death from suicide, substance abuse, medication, RNA quality and brain pH were extracted as background information. Unless specifically stated, suicide was not assumed as cause of death. Study design information, such as neuroinflammatory markers measured, measuring techniques and in which brain regions the measurements were made were all extracted, along with comparative results between schizophrenia and healthy controls. Thus, all results discussed below are relative to controls unless otherwise stated.

RESULTS

Following removal of duplicates, the search yielded 5385 unique results. A total of 5168 articles were excluded based on either title or abstract. The remaining 217 articles were fully screened for potential inclusion. Out of those remaining 217 articles, only 115 articles met the inclusion criteria. Four more articles were found in the reference section of papers yielded from the search (Figure 1).




Figure 1. Systematic search results.

ASTROGLIA

Our search yielded a total of 42 studies which assessed astrocytes in postmortem brain in schizophrenia (Table 1).

Of those 42 studies, 33 studies evaluated potential differences in astrocytes in schizophrenia by measuring GFAP expression or immunoreactive distribution. Out of the 33 studies evaluating GFAP expression, 21 did not detect any schizophrenia-associated changes, 6 studies reported a decrease in GFAP expression, whereas 6 studies reported increased expression.

The first study to evaluate GFAP was published in 1986 by Robert *et al.*⁴³ In their study of the temporal cortex of 5 schizophrenic patients, immunohistochemical analysis found no differences in GFAP staining in schizophrenia brains compared with healthy controls,⁴³ and was confirmed in a subsequent study with a larger cohort.⁴⁴ Similarly, many quantitative immunohistochemical studies found no differences in GFAP cell density in several other brain regions including the hippocampus,^{45,46} amygdala,^{47,48} subiculum,^{45,49} mediodorsal thalamus,⁵⁰ caudate,^{50,51} periventricular nucleus,⁵¹ nucleus basalis,⁵² premotor cortex,⁴⁹ dorsolateral prefrontal cortex,⁵³ midfrontal cortex,^{45,46} orbitofrontal cortex,^{45,46} entorhinal cortex,^{45–47,49,54} visual cortex,⁴⁵ calcarine cortex⁴⁶ and anterior cingulate cortex.⁵³ When compared with Alzheimer's and Huntington's disease patients, schizophrenic patients had lower GFAP-labeled cells.^{43,45,46} However, schizophrenic patients presenting with dementia had significantly higher GFAP cell density than schizophrenic patients without dementia in multiple brain regions including hippocampus, entorhinal cortex and orbitofrontal cortex.⁴⁵ GFAP was also reported to be correlated with age.⁵⁴ Although Hercher *et al.*⁵⁵ also found no differences in GFAP cell density in the dorsolateral prefrontal cortex in schizophrenia, they did find a decrease in GFAP fraction area and increased clustering. Phosphorylated GFAP was investigated in one immunohistochemical study. In a cohort of 15 patients, no difference in phosphorylated GFAP was observed between schizophrenic brains and those of healthy controls in the hippocampus.⁵⁶ The authors did note, however, a decrease in phosphorylated GFAP-labeled cells in the dorsolateral prefrontal cortex next to blood vessels.⁵⁶

Similar to the immunohistochemical studies mentioned above, multiple studies reported no increases in GFAP expression measured by other methods. No increase in GFAP mRNA expression was detected in the prefrontal⁵⁷ and cingulate cortices⁵⁸ of schizophrenics. Beasley *et al.*⁵⁹ found no differences in GFAP in the anterior limb of internal capsule of schizophrenia compared with healthy controls as measured by enzyme-linked immunosorbent assay. Western blot analysis, similarly, found no increase in GFAP protein concentration in the cerebellum,^{60,61} frontal cortex,^{61,62} prefrontal cortex,^{63–65} visual cortex,⁶⁴ occipital cortex,⁶¹ temporal cortex,⁶¹ parietal cortex,⁶² thalamus⁶¹ and pons⁶¹ of schizophrenic patients. Another study evaluating GFAP protein expression by western blot of various brain regions of 23 schizophrenics, including the dorsolateral prefrontal cortex, visual cortex, anterior cingulate cortex, hippocampus and temporal gyrus, failed to detect any changes in GFAP protein expression in schizophrenia, except for a significant decrease in the anterior cingulate cortex.⁶⁶

A few studies have detected differences in GFAP protein expression. Williams *et al.*⁶⁷ reported a decrease in GFAP cell density in the subgenual cingulate cortex and the corpus callosum in both the gray and white matter in a cohort of 10 schizophrenic patients compared to healthy controls. More specifically, another study found a decrease in number of fibrillary astrocytes in the subgenual anterior cingulate cortex.⁶⁸ The authors, however, found no differences in gemistocytic astrocytes.⁶⁸ In a separate study, the same group also found a decrease in GFAP cell density in the substantia nigra.⁶⁹ Falkai *et al.*⁴⁹ reported a decrease in GFAP cell density in the left inferior horn in men, whereas no effect was observed in women. On the other hand, Rajkowska *et al.*⁷⁰ reported, in a cohort of 9 schizophrenic brains, an increase

in GFAP cell density in layer V of the dorsolateral prefrontal cortex, whereas GFAP labeling area was reduced by 32%. These changes were layer specific, as no differences were detected in layer III and IV.⁷⁰ This is slightly different from what Toro *et al.*⁷¹ observed, where an increase in GFAP, as measured by autoradiography, were observed in layers II, III and IV of the prefrontal cortex in schizophrenia. Importantly, this increase in GFAP was correlated with antipsychotic use. A decrease in GFAP in the orbitofrontal cortex was also observed.⁷¹ The authors proposed that the increase in prefrontal cortex was due to medication use whereas the decrease in the orbitofrontal cortex was due to the disease.⁷¹ Markova *et al.*⁷² reported increased GFAP positive cell area and reduced anisotropy, indicating gliosis, in the olfactory tubercle in schizophrenia. This is in agreement with another study where GFAP-labeled cells had changed in morphology in the prefrontal cortex of schizophrenics, being more stained and stunted, whereas also having a 2.4-fold increase in protein concentration and 30% increase in mRNA expression.⁷³ Other studies have also shown that GFAP mRNA expression changes in schizophrenia. Barley *et al.*⁷⁴ found that schizophrenic patients had increased GFAP mRNA expression in the putamen and mediodorsal thalamic nuclei. Like Toro *et al.*, increases in GFAP expression were correlated with duration of neuroleptic treatment.⁷⁴ Although Catts *et al.*⁷⁵ found no changes in GFAP mRNA expression in the dorsolateral prefrontal cortex between schizophrenic patients and healthy controls, a difference was observed in schizophrenia patients when they were stratified based on the presence of other neuroinflammatory markers including serpin peptidase inhibitor (SERPIN) A3, IL-1 β , IL-6 and IL-8. Individuals with elevated neuroinflammation had a larger proportion of hypertrophic astrocytes compared with low neuroinflammation subjects.⁷⁵ On the other hand, GFAP mRNA, as measured by riboprobe was decreased in the white matter of the anterior cingulate cortex.⁷⁶ This effect, however, was not seen in the gray matter.⁷⁶

Other astrocytic markers have also been measured in postmortem brain specimen of patients with schizophrenia. Hwang *et al.*⁷⁷ showed increases in apolipoprotein 1 and adenosine A2A receptor mRNA expression, markers of perivascular astrocytes and implicated in inflammatory responses, in the hippocampus in schizophrenia. Similarly, along with increases in GFAP, schizophrenia was associated with increases in aldehyde dehydrogenase (ALDH)1 mRNA in several brain regions including the putamen, anteroventral nucleus, internal capsule and mediodorsal thalamic nucleus.⁷⁴ In contrast, two other studies found no association between schizophrenia and ALDH1L1 mRNA measured in the deep layer of the cingulate cortex⁵⁸ and protein concentration in the dorsolateral prefrontal cortex.⁶⁵ Similar results were observed for GFAP and other astrocytic markers including vimentin,^{58,65} excitatory amino-acid transporter (EAAT)1⁶⁵ and phosphate-activated glutaminase.⁵⁸ Katsel *et al.*,⁵⁸ however, did find several other astrocytic markers, including S100b and EAAT2 mRNA to be downregulated in the cingulate cortex in schizophrenia. Differences in expression of various astrocytic markers may point to different types of astrocytes being affected in schizophrenia.⁵⁸ S100b has been measured in a few other studies with mixed results. While one study found decreases in S100b protein measured by western blot analysis in the corpus callosum,⁷⁸ another found no effect in several brain regions including Brodmann area (BA) 9, 10, 40 and 46.⁶² When separating paranoid schizophrenia from residual schizophrenia, one study found an increase in S100b-positive cells in paranoid schizophrenia compared with both residual schizophrenia and healthy controls in the dorsolateral prefrontal cortex.⁷⁹ No effect was seen, however, in the white matter, as well as other brain regions such as hippocampus, mediodorsal thalamus, anterior cingulate cortex, superior temporal cortex and orbitofrontal cortex.⁷⁹

Astrocytes have also been identified in postmortem brains by microscopic analysis with other staining techniques. Casanova

Table 1. Astrocytes in postmortem schizophrenia brain

Author	Brain bank	n	Sex (m/f)	Age	Death from suicide	Brain region	Technique	Inflammatory markers	Results
Altshuler et al. ⁴⁸	SFNC	scz 9 ctr 14	scz 5/4 ctr 8/6	scz 45 ctr 47	scz 3	Basolateral nucleus of the amygdala	IHC	GFAP	↔
Arnold et al. ⁴⁵	Prospective study	scz 7* scz+d 14# ctr 12	scz 3/4 scz+d 6/8 ctr 5/7	scz 74 scz+d 82 ctr 75	NA	EC*, SB#, CA3*, CA1*, DG*, MFC*, OFC#, VC*	IHC	GFAP#, VIM*	↔ *↑#
Arnold et al. ⁴⁶	Prospective study	scz 23 ctr 14	scz 8/15 ctr 6/8	scz 80 ctr 75	NA	EC (BA 28) CA1 HPC, SB MFC (BA9 and 46), OFC (BA11), CL (BA17)	IHC	GFAP	↔
Barley et al. ⁷⁴	SFNC	Varies across brain regions	Varies across brain regions	Varies across brain regions	NA	AVN, PU, IC, MTN	PCR	GFAP, ALDH1	↑
Beasley et al. ⁵⁹	NYSPIBC	scz 15 ctr 13	scz 9/6 ctr 10/3	scz 54 ctr 51	None	Anterior limb of internal capsule	ELISA	GFAP	↔
Casanova et al. ⁸⁰	NC	scz 6 ctr 7	scz 4/2 ctr 4/3	scz 39 ctr 61	NA	DG, PP	Holzer's Technique	Astrocytes	↔
Catts et al. ⁷⁵	NSWTRC	scz 37 ctr 37	scz 24/13 ctr 30/7	scz 51 ctr 51	scz 8	DLPFC (BA46)	PCR, IHC, WB	GFAP	↔
Damadzic et al. ⁵⁴	(1) CBDBNIMH (2) SFNC	Study (1) scz 7 ctr 8 study (2) scz 14 ctr 15	Study (1) scz 3/4 ctr 3/5 study (2) scz 9/5 ctr 9/6	Study 1 scz 49 ctr 47 study 2 scz 46 ctr 48	Study 1 scz 3 ctr 1 study 2 scz 3	EC	IHC	GFAP	↔
Dean et al. ⁶²	NA	scz 20 ctr 20	scz 13/7 ctr 13/7	scz 56 ctr 56	NA	BA9, 10, 40, 46	WB, PCR	S100b, GFAP	↔
Falkai et al. ⁴⁹	DBC	scz 33 ctr 26	scz 14/19 ctr 13/13	scz 54 ctr 53	scz 4	PMC, SB, EC, IH, SVZ3V	IHC	GFAP	↔
Falke et al. ⁵⁰	Prospective study	scz 12 ctr 11	scz 3/9 ctr 7/4	Scz 81 ctr 78	NA	MTN, CT	IHC	GFAP	↔
Fatemi et al. ⁶⁰	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 44 ctr 48	scz 4	lateral CB	WB	GFAP	↔
Feresten et al. ⁶⁵	SMRIAC	scz 35 ctr 35	scz 26/9 ctr 26/9	scz 43 ctr 44	scz 7	DLPFC (BA9)	WB	GFAP#, VIM*, ALDH1L1*, EAAT*	↔ * ↑#
Hercher et al. ⁵⁵	SMRIAC	scz 20 ctr 20	scz 13/7 ctr 14/6	scz 45 ctr 45	scz 4	DLPFC (BA9)	IHC	GFAP	↔
Hwang et al. ⁷⁷	SFNC, SMRIAC	scz 33 ctr 34	scz 23/10 ctr 23/11	scz 44 ctr 46	NA	HPC	PCR, IHC	APOL1, ADORA2A	↑
Karson et al. ⁶¹	DCMEO	scz 25 ctr 28	scz 22/3 ctr 22/6	scz 34 ctr 35	scz 16 ctr 8	FC, TC, OC, CB, TH, pons	WB	GFAP	↔
Karson et al. ⁶³	NA	scz 14 ctr 12	scz 13/1 ctr 11/1	scz 65 ctr 67	NA	PFC (BA10)	WB, northern blot	GFAP	↔
Katsel et al. ⁵⁸	NA	scz 18 ctr 21	scz 10/8 ctr 10/11	scz 78 ctr 77	scz 0	Cingulate cortex (BA24/32)	PCR	GFAP #, S100b*, VIM#, EAAT2*, ALDH1L1#, AQP4*, DIO*, GS*, THBS4*, GL#	↓* ↔ # (deep layer only)
Kolomeets et al. ⁸³	ADMPH	scz 19 ctr 16	scz 11/8 ctr 11/5	scz 54 ctr 56	NA	HPC	Electron microscope	Astrocytes	↔
Markova et al. ⁷²	NA	scz 12 ctr 10	NA	scz 62 ctr NA	NA	Olfactory tubercle	IHC	GFAP	↑
Pakkenberg ⁸²	NA	scz 12 ctr 12	scz 8/4 ctr 66	scz 63 ctr 62	NA	MTN*, AG#, NAS*, PL#	Nissl	Astrocytes	↓* ↔ #
Pantazopoulos et al. ⁴⁷	HBTRC	scz 11 ctr 15	scz 7/4 ctr 10/5	scz 62 ctr 66	scz 1	AG, EC	IHC	GFAP	↔
Perrone-Bizzozero et al. ⁶⁴	HBTRC	scz 17 ctr 18	scz 17/0 ctr 18/0	scz 44 ctr 48	scz 4 ctr 2	VC (BA17,20) PFC (BA9,10)	WB	GFAP	↔
Radewicz et al. ⁵³	Prospective study	scz 12 ctr 11	NA	scz 80 ctr 72	NA	DLPFC (BA9), ACC (BA24), superior TC (BA22)	IHC	GFAP	↔
Rajkowska et al. ⁷⁰	CCCO	scz 9 ctr 15	scz 2/7 ctr 10/5	scz 47 ctr 47	scz 3	DLPFC (BA9)	IHC	GFAP	↑ (layer V only)

Table 1. (Continued)

Author	Brain bank	n	Sex (m/f)	Age	Death from suicide	Brain region	Technique	Inflammatory markers	Results
Rao <i>et al.</i> ⁷³	HBTRC	scz 10 ctr 10	scz 6/4 ctr 7/3	scz 59 ctr 49	NA	FC (BA10)	IHC, PCR, WB	GFAP	↑
Roberts <i>et al.</i> ⁴³	VIBR	scz 5 ctr 7	scz 1/4 ctr 4/3	scz 39 ctr 51	NA	TL, PC, PU, CT, AG, HPC, TH	IHC	GFAP	↔
Roberts <i>et al.</i> ⁴⁴	Runwell series 1 brain collection	scz 18 ctr 12	scz 14/4 ctr 9/3	scz 69. ctr 55	NA	TL	IHC	GFAP	↔
Schmitt <i>et al.</i> ⁸¹	DBC	scz 10 ctr 10	scz 5/5 ctr 5/5	scz 55 ctr 50	scz 1	CA1,2/3,4, SB	Cresyl violet	Astrocytes	↔
Steffek <i>et al.</i> ⁶⁶	MSMC, BVAMC	scz 23 ctr 27	scz 16/7 ctr 14/13	scz 72 ctr 79	None	ACC*, DLPFC#, VC#, ACC*, HPC#, temporal gyrus#	WB	GFAP	↓* ↔ #
Steiner <i>et al.</i> ⁷⁹	MBC	p scz 9* r scz 9# ctr 16	p scz 5/4 r scz 4/5 ctr 7/9	p scz 56 r scz 54 ctr 56	p scz 3 r scz 2	ACC*, DLPFC#, OFC #, sTC#, HPC#, MTN#	IHC	S100b	↑* ↔ #
Steiner <i>et al.</i> ⁷⁸	WMSH, HUIN	scz 9 ctr 7	scz 5/4 ctr 5/2	scz 68 ctr 65	None	CO	WB, MS	S100b	↓
Stevens <i>et al.</i> ⁵¹	VIBR	scz 5 ctr 7	NA	NA	NA	CT, PVN	IHC	GFAP	↔
Tkachev <i>et al.</i> ⁵⁷	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 44 ctr 48	scz 4	PFC (BA9)	PCR	GFAP	↔
Toro <i>et al.</i> ⁷¹	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 45 ctr 48	scz 4	PFC* (BA9,32,46) OFC# (BA11/47)	IAR	GFAP	↑* ↓ #
Uranova <i>et al.</i> ⁸⁴	MHRC	scz 26 ctr 26	scz 11/15 ctr 21/5	scz 53 ctr 52	NA	PFC (BA10) and VC (BA17)	Electron microscopy	Astrocytic end feet	↑ (except for VC of non p scz)
Williams <i>et al.</i> ⁶⁷	CC	scz 10 ctr 19	scz 5/5 ctr 11/8	scz 58 ctr 66	scz 1	Subgenual cingulate cortex*, CO	IHC	GFAP	↓ (only in layer I*)
Williams <i>et al.</i> ⁵²	CC	scz 13 ctr 16	Scz 6/7 ctr 4/12	scz 57 ctr 55	scz 2	Nucleus basalis	IHC	GFAP	↔
Williams <i>et al.</i> ⁶⁹	CC	scz 12 ctr 13	scz 7/4 ctr 9/4	scz 60 ctr 52	scz 2	Substantia nigra	IHC	GFAP	↓
Williams <i>et al.</i> ⁶⁸	CC	scz 10 ctr 19	scz 5/5 ctr 11/8	scz 58 ctr 66	scz 1	Subgenual cingulate cortex	IHC	GFAP	↓
Webster <i>et al.</i> ⁵⁶	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 44 ctr 48	scz 4	DLPFC, HPC	IHC	Phosphorylated GFAP	↔ (except DLPFC blood vessel labeling)
Webster <i>et al.</i> ⁷⁶	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 45 ctr 48	scz 4	ACC (BA24)	Riboprobe and <i>in situ</i> hybridization	GFAP	↓ (white matter only)

Abbreviations: ACC, anterior cingulate cortex; ADMPH, Anatomical Department of Moscow Psychiatric Hospital; ADORA2A, adenosine A2A receptor; AG, amygdala; ALDH, aldehyde dehydrogenase; APOL, apolipoprotein; AQP, aquaporin; AVN, anteroventral nucleus; BA, Brodmann area; BVAMC, Bronx Veterans Administration Medical Center; CA, cornu ammonis; CB, cerebellum; CBDBNIMH, Clinical Brain Disorder Branch at the National Institute of Mental Health; CC, Corsellis Collection; CL, calcarine cortex; CO, corpus callosum; CT, caudate; ctr, control; CCCO, Cuyahoga Country Coroner's Office; d, dementia; DBC, Dusseldorf Brain Collection, DCMEQ, District of Columbia Medical Examiner's Office; DG, dentate gyrus; DIO, diiodinase; DLPFC, dorsolateral prefrontal cortex; EAAT, excitatory amino-acid transporter; EC, entorhinal cortex; ELISA, enzyme-linked immunoadsorbent assay; FC, frontal cortex; GFAP, glial fibrillary acidic protein; GL, phosphate-activated glutaminase; GS, glutamine synthase; HBTRC, Harvard Brain Tissue Resource Centre; HPC, hippocampus; HUIN, Heidelberg University Institute of Neuropathology; IAR, immunautoradiography; IC, internal capsule; IH, inferior horn; IHC, immunohistochemistry; MBC, Magdeburg Brain Collection; MHRC, Mental Health Research Centre; MFC, midfrontal cortex; MS, mass spectrometry; MSMC, Mount Sinai Medical Centre; MTN, mediadorsal thalamic nucleus; NA, not available; NC, Neuman Collection; NSWTRC, New South Wales Tissue Resource Centre; NYSPIBC, New York State Psychiatric Institute Brain Collection; OC, occipital cortex; OFC, orbitofrontal cortex; PC, parietal cortex; PCR, polymerase chain reaction; PFC, prefrontal cortex; PMC, premotor cortex; PP, perforant path; PU, putamen; PVN, paraventricular nucleus; SB, subiculum scz, schizophrenia; scz (p), paranoid schizophrenia; scz (r), residual schizophrenia; SFNC, Stanley Foundation Neuropathology Consortium; SMRIAC, Stanley Medical Research Institute Array Collection; ST, striatum; SVZ, subventricular zone; TC, temporal cortex; TH, thalamus; THBS, thrombospondin; TL, Temporal lobe; VBBN, Victorian Brain Bank Network; VC, visual cortex; VIBR; Vogt Institute of Brain Research; VIM, vimentin; WB, western blot; WMSH, Wiesloch Mental State Hospital. *, # indicate which variables results are representing.

*et al.*⁸⁰ found no differences in astrocytes identified using Holzer's technique between the hippocampus of six schizophrenia patients and seven healthy controls. Similar to other studies comparing schizophrenic brains to those with Alzheimer's disease,^{45,46} Alzheimer's disease brains had more astrocytes compared to both the schizophrenia and control groups.⁸⁰ Similarly, stereological counting of Nissl stained astrocytes showed no differences in cell counts in the hippocampus,⁸¹ basolateral nucleus of the amygdala⁸² and pallidum.⁸² However, a significant decrease in astrocytes was measured in both the nucleus accumbens and mediodorsal thalamic nucleus.⁸²

Changes in astrocytes in schizophrenia have also been investigated by electron microscopy.⁸³ In a cohort of 19 schizophrenia patients, astrocyte morphology was unchanged in the hippocampus compared with healthy controls.⁸³ However, when patients were separated based on age, increased astrocytes were observed in patients younger than 50 years old, but this effect was lost in older patients. On the other hand, astrocytic end feet were increased in both paranoid and non-paranoid schizophrenia in the prefrontal cortex,⁸⁴ however, this effect was not present in the visual cortex in non-paranoid schizophrenics.⁸⁴

MICROGLIA

From our search, a total of 22 articles reported on microglial markers in postmortem schizophrenic brains (Table 2). Out of these 22 studies, 11 studies reported an increase in microglial markers in postmortem brains, whereas 8 studies found no effect and 3 studies found a decrease in microglial markers.

Bayer *et al.*⁸⁵ found that 3 of 14 schizophrenic patients had positive HLA-antigen D-related (DR) staining, MHC class II molecules involved in antigen presentation, whereas control subjects showed no staining in the hippocampus and frontal cortex. This is in agreement with two subsequent studies, where HLA-DR was increased in the prefrontal cortex,⁸⁶ dorsolateral prefrontal cortex,⁵³ superior temporal gyrus,⁵³ inferior temporal gyrus⁸⁷ and frontal lobe in schizophrenia.⁸⁷ No changes, however, were seen in the cingulate cortex.⁵³ This increase in HLA-DR labeling in the hippocampus appears to be more pronounced in paranoid schizophrenics, as this group has increased HLA-DR compared with both control and residual schizophrenics, although only significantly different from residual schizophrenics.⁸⁸ Immunohistochemistry revealed differences in morphology of HLA-DR-labeled cells in schizophrenia, presenting a stunted and stronger labeling phenotype in the frontal cortex.⁷³ It also has been reported that although patients show stronger HLA-DR labeling in the anterior cingulate cortex, microglia appear to be degenerating.⁸⁹ Calprotectin, a member of the S100 family, co-expressed with microglial marker CD68 and was increased twofold in the dorsolateral prefrontal cortex in schizophrenic patients compared with healthy controls.⁹⁰

Not all studies found significant differences in microglia density. Steiner *et al.*⁹¹ found no differences in HLA-DR protein in various brain regions between schizophrenia and healthy controls, but did note that the two individuals who committed suicide in their cohort did show more HLA-DR labeling. A follow-up study by the same group found a similar lack of effect of diagnosis, but that suicide was accompanied with higher HLA-DR-positive cells.⁹² In a microarray analysis, an increase in HLA-A, MHC I molecules, mRNA expression in the frontal cortex and superior frontal gyrus was observed between schizophrenia and healthy controls in the frontal cortex.⁹³ This effect, however, was not statistically significant when mRNA expression was confirmed by qPCR.⁹³ Schmitt *et al.*⁹⁴ observed, in a microarray analysis of the temporal cortex of 10 schizophrenic patients and controls, lower mRNA expression of HLA-DRB3 and HLA-DPA1, subunits of HLA-DR, in schizophrenia. Similar to Saetre and colleagues, however, this effect was once again lost when analyzed by qPCR.⁹⁴ Similarly,

MHC II-positive cells were also unchanged in the subventricular zone in schizophrenia compared to healthy controls.⁹⁵ Nakatani *et al.*⁹⁶ also found no differences in HLA-DRA mRNA expression in the dorsolateral prefrontal cortex in schizophrenia, despite seeing a difference between control and bipolar disorder. Other microglial markers are also unchanged in schizophrenia. For example, ionized calcium-binding adapter molecule (Iba)1 as measured by immunohistochemistry showed no differences in microglial density in the cingulate cortex or dorsolateral prefrontal cortex.^{55,97} Two prospective studies following patients who developed schizophrenia found no change in CD68 protein in the caudate nucleus,⁵⁰ mediodorsal nucleus of the thalamus,⁵⁰ hippocampus,⁴⁶ and entorhinal⁴⁶ and calcarine⁴⁶ cortices in schizophrenic patients.

Similar decreases in HLA-DRA and HLA-DRB4 mRNA expression were observed in the temporal lobe.⁹⁸ Despite not seeing changes in HLA-DR-positive cells, a separate study found microglial production of quinolinic acid was reduced in the hippocampus, and more specifically in the cornu ammonis (CA)1, of schizophrenic patients.⁹⁹ MHC I protein concentration was lower in the dorsolateral prefrontal cortex in a non-smoking schizophrenic population, whereas no differences were seen in the orbitofrontal cortex.¹⁰⁰ This effect was not seen in a smoking population.¹⁰⁰ Systemic inflammation, however, appears to have a role in potential differences between patients with schizophrenia and healthy controls. In one study, schizophrenic patients with no systemic inflammation showed no differences as compared with healthy controls, but schizophrenics displaying systemic inflammation had lower HLA-A mRNA expression compared with psychiatrically healthy controls with systemic inflammation.¹⁰¹ However, when that same cohort was divided into smokers and non-smokers, regardless of systemic inflammation, HLA-B mRNA expression was increased in schizophrenic patients.¹⁰¹ The authors did report that HLA-A appeared to co-localize with glutamergic neurons.¹⁰¹

UNDIFFERENTIATED GLIAL CELLS

Multiple studies have evaluated glial cells in schizophrenia without the use of cell type-specific markers. Some studies separated the types of glial cells (that is, astrocytes, oligodendrocytes, microglia), as discussed previously. However, many studies using Nissl staining, evaluated the effect of schizophrenia on glial cells without differentiating between cell types. In total, 34 studies evaluated glial cells in schizophrenia, where 25 studies reported no difference, 7 studies found a decrease and 2 found an increase in glial cell densities (Table 3).

Stevens¹⁰² published the first study which met our inclusion criteria on the effect of schizophrenia on glial cells. In a cohort of 18 schizophrenic patients, fibrous gliosis measured by Holzer's staining was more pronounced in several brain regions including the hippocampus, hypothalamus, amygdala, thalamus, and periventricular areas compared to control. Comparable effects were observed in another study, which found increased fibrous gliosis as measured by Holzer's technique in the cerebral cortex of patients with schizophrenia.¹⁰³

The increase in gliosis measured by Holzer's technique appears to differ, however, with a study published shortly after the report by Stevens and colleagues, which found, using a Nissl staining technique, a decrease in glial cell density in the CA3 and CA4 of the hippocampus.¹⁰⁴ No effect of schizophrenia, however, was observed in the CA1 and subiculum.¹⁰⁴ Similar decreases in glia were observed by Giemsa staining in the anterior cingulate cortex¹⁰⁵ and by cresyl violet staining in the temporal cortex¹⁰⁶ and planum temporale.¹⁰⁷ A layer specific decrease in glial cell density measured by cresyl violet staining was observed in three studies, where effects were only in layer V of the dorsolateral prefrontal cortex,¹⁰⁸ layer VI of the anterior cingulate cortex

Table 2. Microglia in postmortem schizophrenia brain

Author	Brain bank	n	Sex (m/f)	Age	Death from suicide	Brain region	Technique	Inflammatory markers	Results
Arnold <i>et al.</i> ⁴⁶	Prospective study	scz 23 ctr 14	scz 8/15 ctr 6/8	scz 80 ctr 75	NA	EC (BA 28) CA1, SB, MFC (BA9 and 46), OFC (BA11), CL (BA17)	IHC	CD68	↔
Bayer <i>et al.</i> ⁸⁵	INUBMC, INMD	scz 14 ctr 13	scz 3/11 ctr 8/5	scz 64 ctr 58	NA	FC, HPC	IHC	HLA-DR	↑
Busse <i>et al.</i> ⁸⁸	MBC	scz (p) 10* scz (r) 7 ctr 11	scz (p) 5/5 scz (r) 4/3 ctr 6/5	scz (p) 50 scz (r) 56 ctr 56	scz 5#	HPC	IHC	HLA-DR	↑*#
Comte <i>et al.</i> ⁹⁵	SFNC	Scz 15 ctr 15	scz 9/6 ctr 9/6	scz 44 ctr 48	scz 4	SVZ	IHC	MHC II	↔
Connor <i>et al.</i> ⁹⁷	HBTRC	scz 22 ctr 45	scz 9/13 ctr 24/21	scz 68 ctr 70	NA	ACC (BA24), DLPFC	IHC	Iba1	↔
Durrenberger <i>et al.</i> ⁹⁸	BBPDGU	scz 10 ctr 10	scz 5/5 ctr 5/5	scz 66 ctr 61	NA	Temporal lobe (BA22)	PCR	HLA-DRA, HLA-DRB4	↓
Falke <i>et al.</i> ⁵⁰	Prospective study	scz 12 ctr 11	scz 3/9 ctr 7/4	scz 81 ctr 78	NA	MTN, CT	IHC	CD68	↔
Fillman <i>et al.</i> ⁸⁶	NSWTRC	scz 37 ctr 37	scz 24/13 ctr 30/7	scz 53 ctr 51	NA	DLPFC (BA46)	WB, IHC	HLA-DR/DP/DQ	↑
Foster <i>et al.</i> ⁹⁰	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 44 ctr 48	scz 4	DLPFC (BA9)	ELISA, IHC	Calprotectin* CD68#	↑* ↔ #
Gos <i>et al.</i> ⁹⁹	MBC	scz 13 ctr 12	scz 7/6 ctr 6/6	scz 51 ctr 49	scz 2	CA1*,2,3, DG	IHC	HLA-DR#, quinolinic acid*	↓* ↔ #
Hercher <i>et al.</i> ⁵⁵	SMRIAC	scz 20 ctr 20	scz 13/7 ctr 14/6	scz 45 ctr 45.3	scz 4	DLPFC (BA9)	IHC	Iba1	↔
Kano <i>et al.</i> ¹⁰⁰	SMRIAC	scz 35 ctr 35	scz 26/9 ctr 26/9	scz 43 ctr 44	scz 7	DLPFC*, OFC#	WB	MHC I	↓* ↔ #
Nakatani <i>et al.</i> ⁹⁶	VIFM	scz 7 ctr 7	scz 3/4 ctr 3/4	scz 61 ctr 61	scz 1	DLPFC (BA46), PC (BA40)	PCR	HLA-DRA	↔
Radewicz <i>et al.</i> ⁵³	Prospective study	scz 12 ctr 11	NA	scz 80 ctr 72	NA	DLPFC (BA9)*, ACC (BA24)#, superior TC (BA22)*	IHC	HLA-DR	↑* ↔ #
Rao <i>et al.</i> ⁷³	HBTRC	scz 10 ctr 10	scz 6/4 ctr 7/3	scz 59 ctr 49	NA	FC (BA10)	IHC, PCR, WB	HLA-DR, CD11b	↑
Saetre <i>et al.</i> ⁹³	SFNC, HBTRC, MBB	scz 55 ctr 55	NA	scz 58 ctr 56	NA	FC (BA8 and 9), superior frontal gyrus	PCR	HLA-A	↔
Schmitt <i>et al.</i> ⁹⁴	BBPDGU	10 per group	scz 5/5 ctr 8/2	scz 66 ctr 61	NA	TC (BA22)	PCR	HLA-DRB3, HLA-DPA1	↔
Sinkus <i>et al.</i> ¹⁰¹	SRCBB	scz 42 ctr 47	scz 28/14 ctr 33/14	scz 51 ctr 53	scz 0 ctr 1	HPC	PCR	HLA-A#, HLA-B*	↑* ↔ #
Steiner <i>et al.</i> ⁹¹	MBC	scz 16* ctr 16	scz 8/8 ctr 8/8	scz 55 ctr 58	scz 2#	HPC, ACC, DLPFC, MTN	IHC	HLA-DR	↔* ↑#
Steiner <i>et al.</i> ⁹²	MBC	scz 16* ctr 10	scz 7/9 ctr 5/5	scz 54 ctr 55	scz 6#	HPC*, DLPFC#, ACC#, MTN#	IHC	HLA-DR	↔* ↑#
Wierzba-Bobrowicz <i>et al.</i> ⁸⁹	NA	scz 12 ctr 7	scz 0/12 ctr 0/6	scz 59 ctr 56	NA	Frontal lobe, cingulate gyrus (BA24)	IHC	HLA-DP/DQ/DR	↑
Wierzba-Bobrowicz <i>et al.</i> ⁸⁷	NA	scz 9 ctr 6	NA	scz 56 ctr 56	NA	Gyrus temporal inferior (BA20), gyrus cinguli (BA24)	IHC	HLA-DP/DQ/DR	↑

Abbreviations: ACC, anterior cingulate cortex; BA, Brodmann area; BBPDGU, Brain Bank for Psychiatric Diseases at the Gottingen University; CA, cornu ammonis; CD, cluster of differentiation; CL, calcarine cortex; CT, caudate; ctr, control; DG, dentate gyrus; DLPFC, dorsolateral prefrontal cortex; EC, entorhinal cortex; ELISA, enzyme-linked immunosorbent assay; FC, frontal cortex; HBTRC, Harvard Brain Tissue Resource Centre; HLA, Human Leukocyte Antigen; HPC, hippocampus; IHC, immunohistochemistry; Iba, ionized calcium-binding adaptor molecule; INMD, Institute for Nervous and Mental Diseases; INUBMC, Institute of Neuropathology, University of Bonn Medical Centre; MBB, Maudsley Brain Bank; MBC, Magdeburg Brain Collection; MHC, major histocompatibility complex; MFC, midfrontal cortex; MTN, mediodorsal thalamic nucleus; NA, not available; NSWTRC, New South Wales Tissue Resource Centre; OFC, orbitofrontal cortex; PC, parietal cortex; PCR, polymerase chain reaction; SB, subiculum; scz, schizophrenia; scz (p), paranoid schizophrenia, scz (r), residual schizophrenia; SFNC, Stanley Foundation Neuropathology Consortium; SMRIAC, Stanley Medical Research Institute Array Collection; SRCBB, Schizophrenia Research Center Brain Bank; SVZ, subventricular zone; TC, temporal cortex; VIFM, Victorian Institute of Forensic Medicine; WB, western blot.

*, # indicate which variables results are representing.

Table 3. Undifferentiated glial cells and postmortem schizophrenia brain

Author	Brain bank	n	Sex (m/f)	Age	Death from suicide	Brain region	Technique	Inflammatory markers	Results
Beasley <i>et al.</i> ¹²⁹	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 44 ctr 48	scz 4	Planum temporal	Cresyl violet	Glia	↔
Beasley <i>et al.</i> ¹⁰⁷	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 44 ctr 48	scz 4	Planum temporal	Cresyl violet	Glia	↓
Beckmann and Lauer ¹³³	WBC	scz 9 ctr 9	scz 9/0 ctr 9/0	scz 55 ctr 52	scz 1	ST, PU, NAS, CT	Gallocyanin	Glia	↔
Benes <i>et al.</i> ¹¹⁰	HBTRC	scz 10 ctr 10	NA	scz 60 ctr 66	scz 1	PFC (BA10)#, motor cortex (BA4)*, cingulate cortex (BA24)#	Cresyl violet	Glia	↓* (only layer III) ↔ #
Benes <i>et al.</i> ¹²⁵	HBTRC	scz 9 scz+md 9 ctr 12	NA	scz 53 scz+md 49 ctr 59	NA	PFC (BA10), ACC (BA24)	Cresyl violet	Glia	↔
Benes <i>et al.</i> ¹²³	HBTRC	scz 11 ctr 12	scz 7/4 ctr 7/5	scz 52 ctr 58	scz 5	ACC (BA24)	Cresyl violet	Glia	↔
Bezchlibnyk <i>et al.</i> ¹¹²	SFNC	scz 13 ctr 15	scz 8/5 ctr 9/6	scz 47 ctr 48	NA	AG	Nissl	Glia	↔
Bogerts <i>et al.</i> ¹³⁰	VIBR	scz 6 ctr 9	scz 2/6 ctr 5/4	scz 51 scz 43	NA	SN	Cresyl violet	Glia	↔ (reduction in size)
Brauch <i>et al.</i> ¹⁰⁶	SNFC	scz 13 ctr 14	NA	scz 46 ctr 47	NA	TC	Cresyl violet	Glia	↓
Bruton <i>et al.</i> ¹⁰³	NA	scz 48 ctr 56	NA	NA	NA	FC, PC, TC	Holzer's Technique	Glia	↑
Chana <i>et al.</i> ¹²⁴	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 45 ctr 48	scz 7	ACC (BA24)	Cresyl violet	Glia	↔
Chana <i>et al.</i> ¹²¹	SFNC	scz 14 ctr 15	NA	NA	NA	MTN	NA	Glia	↔
Cotter <i>et al.</i> ¹⁰⁹	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 45 ctr 48	scz 7	ACC	Cresyl violet	Glia	↔
Cotter <i>et al.</i> ¹⁰⁸	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 45 ctr 48	scz 7	DLFPC (BA9, 46)	Cresyl violet	Glia	↓ (only layer V)
Cotter <i>et al.</i> ¹²²	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 44 ctr 48	scz 4	Heschl's gyrus (BA41) (layer 3 and 5)	Cresyl violet	Glia	↔
Cotter <i>et al.</i> ¹²⁷	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 45 ctr 48	scz 7	OFC	Cresyl violet	Glia	↔
Crow <i>et al.</i> ¹³⁴	NA	scz 22 ctr 26	NA	NA	NA	Temporal horn	Holzer's Technique, IHC	Glia, diazepam binding inhibitor-like	↔
Cullen <i>et al.</i> ¹²⁰	NA	scz 10 ctr 10	scz 6/4 ctr 6/4	scz 60 ctr 60	NA	Frontal gyrus (BA9)	Cresyl violet	Glia	↔
Di Rosa <i>et al.</i> ¹¹⁹	NA	scz 11 ctr 13	scz 6/5 ctr 7/6	scz 66 ctr 68	scz 1	Fusiform gyrus	Cresyl violet	Glia	↔
Falkai and Bogerts ¹⁰⁴	VIBR	scz 13 ctr 11	scz 2/11 ctr 7/4	scz 43 ctr 43	scz 1	CA1#, 3*, 4,* PSB,* SB#	Nissl	Glia	↓* ↔ #
Falkai <i>et al.</i> ¹¹⁸	VIBR	scz 13 ctr 11	scz 11/2 ctr 7/4	scz 43 ctr 43	NA	EC	Nissl	Glia	↔
Hoistad <i>et al.</i> ¹³²	NA	scz 13 ctr 13	scz 13/0 ctr 13/0	scz 52 ctr 52	scz 3	ACC (BA24)	Gallocyanin	Glia	↔
Jonsson <i>et al.</i> ¹²⁸	NA	scz 4 ctr 8	scz 4/0 ctr 8/0	scz 82 ctr 77	NA	HPC	Cresyl violet	Glia	↔
Kurumaji <i>et al.</i> ¹¹¹	NA	scz 13 ctr 10	scz 8/5 ctr 7/3	scz 60 ctr 67	NA	PFC#, TC#, OC*, PC*, PU*, CT#, SN#, PL#, TH#	Receptor binding assay	[³ H] PK11195 binding (gliosis)	↓* ↔ #
Nasrallah <i>et al.</i> ¹³⁵	NIMH	escz 11 lscz 7 ctr 11	Na	escz 66 lscz 73 ctr 64	NA	CO	Hematoxylin-eosin stain	Glia	↔
Ongur <i>et al.</i> ¹¹⁷	SFNC	scz 11 ctr 11	scz 7/3 ctr 7/4	scz 40 ctr 39	scz 4	sg24	Nissl	Glia	↔
Pennington <i>et al.</i> ¹²⁶	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 46 ctr 48	scz 4	Insular cortex	Cresyl violet	Glia	↔
Rajkowska <i>et al.</i> ¹¹⁵	HTBRC, NIMH, UZ	scz 9 ctr 10	scz 7/2 ctr 6/4	scz 41 ctr 44	scz 5	PFC (BA9), OC (BA17)	Nissl	Glia	↔
Selemon <i>et al.</i> ¹¹³	HTBRC, NIMH, UZ	scz 16 ctr 19	scz 12/4 ctr 10/9	scz 40 ctr 47	scz 10	PFC (BA9), OC (BA17)	Nissl	Glia	↔
Selemon <i>et al.</i> ¹¹⁶	HTBRC, UZ	scz 9 ctr 10	scz 6/3 ctr 7/3	scz 44 ctr 48	scz 5	PFC (BA9,46)	Nissl	Glia	↔
Selemon <i>et al.</i> ¹¹⁴	HBTRC, NIMH	scz 9 ctr 14	scz 6/3 ctr 10/4	scz 56 ctr 54	scz 3	FC (BA44) and DLPFC (BA9)	Nissl	Glia	↔
Selemon <i>et al.</i> ¹³¹	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 45 ctr 48	scz 4	Lateral geniculate nucleus	Nissl	Glia	↔
Stark <i>et al.</i> ¹⁰⁵	NA	scz 12 ctr 14	scz 7/5 ctr 7/7	scz 70 ctr 69	scz 1	ACC (BA24)*, BA32#	Giemsa stain	Glia	↓* ↔ #
Stevens ¹⁰²	SEH	scz 28 ctr 18	scz 13/15 ctr 11/7	scz 41 ctr 37	NA	Multiple brain regions	Holzer's Technique	Glia	↑

Abbreviations: ACC, anterior cingulate cortex; AG, amygdala; BA, Brodmann area; CA, cornu ammonis; CO, corpus callosum; CT; caudate; ctr, control; DBC; Dusseldorf Brain Collection, DLPFC; dorsolateral prefrontal cortex; EC, entorhinal cortex; escz, early onset schizophrenia; FC, frontal cortex; HBTRC; Harvard Brain Tissue Resource Centre; HPC, hippocampus; lscz; late onset schizophrenia; md, mood disturbance; MTN, mediodorsal thalamic nucleus; NA, not available; NAS, nucleus accumbens; OC, occipital cortex; OFC, orbitofrontal cortex; PC, parietal cortex; PFC, prefrontal cortex; PL, pallidum; PSB, presubiculum; PU, putamen; SB, subiculum; scz, schizophrenia; SFNC; Stanley Foundation Neuropathology Consortium; sg, subgenual prefrontal cortex; SN; substantia nigra; ST, striatum; SEH, ST. Elizabeth's Hospital; TC, temporal cortex; TH, thalamus; UZ, University of Zagreb; VIBR, Vogt Institute of Brain Research; WBC, Würzburg Brain Collection.

*, # indicate which variables results are representing.

(statistical significance was lost following multiple corrections)¹⁰⁹ and layer III of the motor cortex.¹¹⁰ The latter study did not detect any differences in both the prefrontal and cingulate cortices.¹¹⁰ Gliosis measured by [³H]PK11195 binding, a ligand which binds to the TSPO receptor found on activated microglia and astrocytes, was reduced in schizophrenia in the occipital cortex, parietal cortex, and putamen but not in the prefrontal cortex, temporal cortex, thalamus, pallidum, substantia nigra and caudate.¹¹¹

Twenty-five studies, however, found no effect of schizophrenia on glial cell density in postmortem brains. In a study of 13 schizophrenic postmortem brains from the Stanley Foundation Neuropathology Consortium, Nissl staining revealed no differences in glial cell density or size in the amygdala.¹¹² Similarly, no changes in glial density were obtained in the prefrontal,^{113–116} frontal,¹¹⁴ subgenual prefrontal,¹¹⁷ occipital^{113,115} and entorhinal¹¹⁸ cortices in schizophrenia compared with healthy controls. By comparison, Huntington's Disease had an ~50% increase in glial cell density compared with healthy controls.¹¹³ Moreover, Huntington's disease had increased density of larger glial cells.¹¹⁵ When glial cell density was measured by cresyl violet staining, no changes were detected between schizophrenia patients and healthy controls in several brain regions including the fusiform cortex,¹¹⁹ prefrontal gyrus,¹²⁰ mediodorsal thalamic nucleus,¹²¹ layer III and V of the Heschl's gyrus,¹²² anterior cingulate cortex,^{123–125} prefrontal cortex,¹²⁵ insular cortex,¹²⁶ orbitofrontal cortex,¹²⁷ hippocampus,¹²⁸ planum temporale,¹²⁹ substantia nigra¹³⁰ and lateral geniculate nucleus.¹³¹ It should be noted that although Bogerts *et al.*¹³⁰ failed to detect a difference in glial cell density in schizophrenia, they did report a significant reduction in glial size in schizophrenia patients. Galocyanin, another staining technique, also did not detect an effect of schizophrenia on glial cell density in the dorsolateral prefrontal cortex of 13 male schizophrenic patients.¹³² Similarly, Beckmann and Lauer¹³³ did not find any significant differences in glial density in several brain regions including the striatum, caudate, putamen and nucleus accumbens. Crow *et al.*¹³⁴ also did not detect a differences in gliosis in the temporal horn and in the periventricular region using Holzer's technique between schizophrenia patients and controls. This was confirmed using diazepam inhibitor binding to evaluate gliosis. In another study, Nasrallah *et al.*¹³⁵ found no differences in glial cell density in the corpus callosum in schizophrenia compared with healthy controls using hematoxylin and eosin staining. The authors did note that gliosis rating scores were higher in late onset schizophrenia compared with early onset and control patients.¹³⁵

CYTOKINES AND CHEMOKINES

Ten studies evaluated cytokine and chemokine expression in postmortem brains of schizophrenic patients (Table 4). Two studies reported no difference in IL-1 β mRNA in the prefrontal cortex,^{86,136} despite measuring increases IL-1RA,¹³⁶ IL-6 (ref. 86) and IL-8 mRNA.⁸⁶ IFN- γ , measured by enzyme-linked immunosorbent assay, was reported to be increased in the prefrontal cortex of 35 schizophrenia patients compared to unaffected controls.¹³⁷ However, Rao *et al.* reported 150% and 3.9 fold increases in IL-1 β protein and mRNA respectively in the frontal cortex of schizophrenics. TNF- α protein and mRNA concentrations were also increased, 76% and 2.3-fold respectively, in schizophrenic patients.⁷³ In a study of 19 schizophrenics, TNF- α receptor 1 mRNA was increased in the dorsolateral prefrontal and cingulate cortices compared to controls, whereas soluble TNF- α protein, transmembrane TNF- α protein and TNF- α receptor 2 mRNA concentrations were unchanged.¹³⁸

A microarray analysis, followed by qPCR validation, found a decrease in IL-8 and IL-1 α mRNA expression in the temporal cortex of 10 schizophrenic patients as compared with healthy control patients. However, increases detected in the microarray were not

Table 4. Cytokine and chemokine in postmortem schizophrenia brain

Author	Brain bank	n	Sex (m/f)	Age	Death from suicide	Brain region	Technique	Inflammatory markers	Results
Dean <i>et al.</i> ¹³⁸	VBBN	scz 19 ctr 20	scz 15/4 ctr 16/4	scz 48 ctr 47	scz 8	DLPFC (BA46), ACC (BA24)	WB, PCR	sTNF- α #, tmTNF- α #, TNF- α receptor 1*, 2#	↑* ↔ #
Durrenberger <i>et al.</i> ⁹⁸	BBPDGU	scz 10 ctr 10	scz 5/5 ctr 5/5	scz 66 ctr 61	NA	TL (BA22)	PCR	IL-13RA1	↓
Fillman <i>et al.</i> ⁸⁶	NSWTRC	scz 37 ctr 37	scz 24/13 ctr 30/7	scz 51 ctr 51	NA	DLPFC (BA46)	PCR, WB, IHC	IL-8*, IL-6*, IL-1 β #	↓* ↔ #
Fillman <i>et al.</i> ¹³⁹	SMRIAC	scz 35 ctr 35	scz 26/9 ctr 26/9	scz 43 ctr 44	scz 7	Middle frontal gyrus	PCR	IL-6#, IL-8*, IL-1 β #, IL18#, TNF- α #	↓* ↔ #
Harris <i>et al.</i> ¹³⁷	SMRIAC	scz 35 ctr 33	scz 26/9 ctr 25/8	scz 43 ctr 45	NA	BA10	ELISA	IFN- γ	↑
Nakatani <i>et al.</i> ⁹⁶	VIFM	scz 7 ctr 7	scz 3/4 ctr 3/4	scz 61 ctr 61	scz 1	DLPFC (BA46), PC (BA40)	PCR	CCL3	↑
Rao <i>et al.</i> ⁷³	HBTRC	scz 10 ctr 10	scz 6/4 ctr 7/3	scz 59 ctr 49	NA	FC (BA10)	PCR, WB	TNF- α , IL-1 β	↑
Schmitt <i>et al.</i> ⁹⁴	BBPDGU	scz 10 ctr 10	scz 5/5 ctr 8/2	scz 66 ctr 61	NA	TC (BA22)	PCR	IL-8*, IL-1 α *, CCL2#, IL-1 β #	↓* ↔ #
Toyooka <i>et al.</i> ¹³⁶	NA	scz 22 ctr 23	scz 16/6 ctr 14/9	scz 59 ctr 66	NA	PFC (BA46)*, posterior hypothalamic region, PC (BA 1-3), PU PFC (BA9)	PCR, WB	IL-1 β #, IL-1RA*	↓* ↔ #
Volk <i>et al.</i> ¹⁵⁵	ACOME	scz 62 ctr 62	scz 47/15 ctr 47/15	scz 48 ctr 49	scz 16		PCR	IL-1 β *, IL-6*, IL-8#, IFN- β *	↑* ↔ #

Abbreviations: ACC, anterior cingulate cortex; BA, ACOME, Allegheny County Office of the Medical Examiner; BBPDGU, Brain Bank for Psychiatric Diseases at the Gottingen University, CCL, chemokine (c-c motif) ligand; CCR, chemokine (c-c motif) receptor; ctr, control; DLFPFC, dorsolateral prefrontal cortex; ELISA; enzyme-linked immunosorbent assay; FC, frontal cortex; HBTRC; Harvard Brain Tissue Resource Centre; IHC, IFN, interferon; IL, interleukin; NA, not available; NSWTRC; New South Wales Tissue Resource Centre; PC, parietal cortex; PU, putamen; PCR, polymerase chain reaction; scz, schizophrenia; SMRIAC, Stanley Medical Research Institute Array Collection; sTNF, soluble TNF; TC, temporal cortex; TL, temporal lobe; tmTNF, transmembrane TNF; TNF, tumor necrosis factor; VBBN, Victorian Brain Bank Network; VIFM, Victorian Institute of Forensic Medicine; WB, western blot.
*, # indicate which variables results are representing.

reproduced by qPCR for cytokines and chemokines such IL-1 β , and CCL2.⁹⁴ Another study also found a decrease in IL-8 mRNA in the middle frontal gyrus in schizophrenia, whereas IL-1 β , TNF- α , IL-18 and IL-6 were not changed.¹³⁹ Two more microarray studies also found decreases in expression, with CCL3 being reduced ninefold in the prefrontal cortex⁹⁶ and IL-13RA reduced in the temporal lobe.⁹⁸

ARACHIDONIC ACID CASCADE

Seven studies have evaluated the arachidonic acid cascade in postmortem schizophrenic brains (Table 5).

Regional differences in concentration of cytosolic prostaglandin E synthase (PGES) protein were reported in schizophrenia compared with healthy controls. In schizophrenia, cytosolic PGES was elevated in the prefrontal cortex, but no changes were observed in the temporal and occipital cortices.¹⁴⁰ COX-1 and 2, enzymes regulating the production of prostaglandin E₂, were not altered in the brains of schizophrenics.¹⁴⁰ No changes in COX-2 mRNA expression were also observed in the dorsolateral prefrontal cortex^{86,141} and middle frontal gyrus,¹³⁹ whereas COX-1 mRNA expression was unchanged in the dorsolateral prefrontal cortex.¹⁴¹ Similarly, immunohistochemical analysis of the hippocampus shows no differences in COX-2-positive cell density between schizophrenia and healthy controls.¹⁴² It should be noted that age did affect COX-1 and COX-2 mRNA expression in schizophrenia, with older schizophrenia patients having increased COX-1 and decreased COX-2 mRNA expression.¹⁴¹ ALOX5AP, a protein regulating 5-lypoxygenase (LOX) activity, was found to have lower mRNA expression in the temporal lobe of 66 schizophrenia patients compared with control patients.⁹⁸

In contrast, Rao *et al.* observed no changes in cytosolic PGES mRNA and protein in the frontal cortex in schizophrenia. They also reported no changes in other arachidonic cascade enzymes, such as calcium-independent phospholipase (PLA)₂, LOX5, LOX12, LOX15 and microsomal PGES. They did, however, find COX-2 to be increased in schizophrenia, along with cPLA₂ and sPLA₂.⁷³

SUBSTANCE P

Substance P has been measured in postmortem brains of patients with schizophrenia in 11 studies (Table 6).

One study evaluated preprotachykinin A, a precursor to substance P, and reported that mRNA measured by *in situ* hybridization is decreased in the basal and lateral nuclei of the amygdala, whereas no changes were measured in the temporal cortex.¹⁴³ Similarly, the density of cells containing preprotachykinin A mRNA measured by *in situ* hybridization is also not changed in the caudate and putamen in schizophrenia.¹⁴⁴ Substance P density in multiple brain regions, including substantia nigra,¹⁴⁵ caudate nucleus,¹⁴⁶ frontal cortex,¹⁴⁶ basal ganglia¹⁴⁶ and hypothalamus,¹⁴⁶ detected by radioimmunoassay, is not different in schizophrenia compared with healthy controls. Psychosis without schizophrenia, such as affective disorder and unspecified functional psychosis, did exhibit higher substance P protein concentrations.¹⁴⁶ An immunohistochemical study also did not detect any changes in substance P in the basal ganglia of six schizophrenia patients compared with unaffected controls.¹⁴⁷

Two studies, however, have reported differences in substance P concentration in schizophrenia. Toru *et al.*¹⁴⁸ found a significant increase in substance P detected by radioimmunoassay in the orbitofrontal cortex and hippocampus, and in antipsychotic medication users in the thalamus, substantia nigra and temporal cortex.¹⁴⁸ Similarly, Roberts *et al.* found increased hippocampal substance P, but no changes were seen in multiple brain regions including the amygdala, thalamus, basal ganglia, and temporal, frontal, parietal and cingulate cortices.¹⁴⁹

Table 5. Arachidonic acid cascade in postmortem schizophrenia brain

Author	Brain bank	n	Sex (m/f)	Age	Death from suicide	Brain region	Technique	Inflammatory markers	Results
Durrenberger <i>et al.</i> ⁹⁸	BBPDGU	scz 10 ctr 10	scz 5/5 ctr 5/5	scz 66 ctr 61	NA	Temporal lobe (BA22)	PCR	ALOX5AP	↓
Fillman <i>et al.</i> ⁸⁶	NSWTRC	scz 37 ctr 37	scz 24/13 ctr 30/7	scz 51 ctr 51	NA	DLPFC (BA46)	PCR	PTGS2	↔
Fillman <i>et al.</i> ¹³⁹	SMRIAC	scz 35 ctr 35	scz 26/9 ctr 26/9	scz 43 ctr 44	scz 7	Middle frontal gyrus	PCR	PTGS2	↔
Maida <i>et al.</i> ¹⁴⁰	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 45 ctr 48	scz 4	PFC (BA8)*, TC (BA21 and BA22)# OC (BA18)#	WB, IHC	COX-1#, COX-2 #, cPGE ₂	↓* ↔#
Rao <i>et al.</i> ⁷³	HBTRC	scz 10 ctr 10	scz 6/4 ctr 7/3	scz 59 ctr 49	NA	FC (BA10)	PCR, WB	COX-1#, COX-2*, LOX5#, LOX12#, LOX15#, cPLA ₂ *, sPLA ₂ *, iPLA ₂ #, cPGES#, mPGES#	↑* ↔#
Tang <i>et al.</i> ¹⁴¹	VBBN	scz 38 ctr 38	NA	scz 43 ctr 44	NA	DLPFC (BA46)	PCR	PTGS1, PTGS2, PTGER3, CYP4Z1	↔
Yokota <i>et al.</i> ¹⁴²	NA	scz 17 ctr 22	scz 12/5 ctr 13/9	scz 69 ctr 71	scz 0	HPC	IHC	COX-2	↔

Abbreviations: ALOX5AP, 5-lypoxygenase activating protein; BA, Brodmann Area; BBPDGU, Brain Bank for Psychiatric Diseases at the Göttingen University; ctr, control; COX, cyclooxygenase; cPGE, cytosolic prostaglandin E; FC, frontal cortex; CYP, cytochrome P450; HBTRC, Harvard Brain Tissue Resource Centre; IHC, immunohistochemistry; LOX, lipoxygenase; NA, not available; NSWTRC, New South Wales Tissue Resource Centre; OC, occipital cortex; PCR, polymerase chain reaction; PLA, phospholipase; PFC, prefrontal cortex; PGES, prostaglandin E synthase; PTGS, prostaglandin endoperoxide synthase; PTGER, prostaglandin E receptor 3; scz, schizophrenia; SFNC, Stanley Foundation Neuropathology Consortium; SMRIAC, Stanley Medical Research Institute Array Collection, TC, temporal cortex; VBBN, Victorian Brain Bank Network; WB, western blot.
* , # indicate which variables results are representing.

Table 6. Substance P in postmortem schizophrenia brain

Author	Brain bank n	Sex (m/f)	age	Death from suicide	Brain region	Technique	Inflammatory markers	Results
Burnet and Harrison ¹⁵¹	SFNC	scz 13 ctr 14	scz 44 ctr 47	scz 3	ACC	AR	[¹²⁵ I]BH-substance P binding (NK1 receptor)	↔
Carletti <i>et al.</i> ¹⁴³	SFNC	scz 14 ctr 15	scz 44 ctr 48	scz 4	AG*, TC#	<i>In situ</i> hybridization binding assay	Preprotachykinin A*, NK1 receptor#	↑* ↔ #
Harrington <i>et al.</i> ¹⁴⁴	NA	scz 4 ctr 5	scz 71 ctr 69	NA	CT, PU	<i>In situ</i> hybridization	Preprotachykinin A	↔
Iadarola ¹⁴⁵	DCCO	scz 12 ctr 9	scz 33 ctr 45	scz 9	SN	RIA	Substance P	↔
Kleinman <i>et al.</i> ¹⁴⁶	DCCO	scz 40 ctr 18	scz 48 ctr 50	NA	FC, CT, NAS, PU, GB, HPL	RIA	Substance P	↔ (increased in other non-schizophrenia psychotic disorders)
Rioux <i>et al.</i> ¹⁵⁰	NA	scz 5 ctr 5	scz 70 ctr 70	NA	NAS#, PU*, CT#	AR	[¹²⁵ I]BH-substance P binding (NK1 receptor)	↔* ↑#
Roberts <i>et al.</i> ¹⁴⁹	NA	scz 14 ctr 12	scz 62 ctr 82	scz 2	TC (BA21/22)*, FC (BA4)*, PC (BA7)*, CI (BA24)*, HPC#, AG*, TH*, BG*	RIA	Substance P	↔* ↑#
Tooney <i>et al.</i> ¹⁵²	NSWTRC	scz 6 ctr 6	scz 44 ctr 43	scz 2 ctr 3	PFC (BA9)	IHC	NK1 receptor	↑ (except layer VI)
Toru <i>et al.</i> ¹⁴⁸	NA	scz 14 ctr 10	scz 58 ctr 67	NA	BG*, SN*, TH*, HPC*, TC*, PFC*, PC*, OFC#	RIA	Substance P	↔* ↑#
Weidenhofer <i>et al.</i> ¹⁵³	NSWTRC	scz 12 ctr 15	scz 48 ctr 48	scz 3	AG	IHC, PCR	NK1 receptor	↔
Zech and Bogerts ¹⁴⁷	NA	scz 1/5 ctr 3/2	scz 31 ctr 45	NA	BG	IHC	Substance P	↔

Abbreviations: ACC, anterior cingulate cortex; AG, amygdala; AR, autoradiography; BA, Brodmann Area; BG, basal ganglia; CI, cingulate cortex; CT, caudate; DCCO, District of Columbia Coroner's Office; FC, frontal cortex; HPC, hippocampus; HPL, hypothalamus; IHC, immunohistochemistry; NA, not available; NAS, nucleus accumbens; NK1, neurokinin 1; NSWTRC, New south wales tissue resource centre; OFC, orbitofrontal cortex; PC, parietal cortex; PCR, polymerase chain reaction; PFC, prefrontal cortex; PU, putamen; RIA, radioimmunoassay; scz, schizophrenia; SN, substantia nigra; SFNC, Stanley Foundation Neuropathology Consortium; TC, temporal cortex; TH, thalamus.
*, # indicate which variables results are representing.

Five studies evaluated substance P binding to substance P neurokinin 1 receptor. Autoradiography found no changes in neurokinin 1 receptor density in the putamen,¹⁵⁰ anterior cingulate cortex¹⁵¹ and temporal cortex.¹⁴³ There was, however, an increase in receptor density in the caudate¹⁵⁰ and nucleus accumbens.¹⁵⁰ Immunohistochemical analysis found similar increases in substance P receptor in the prefrontal cortex in schizophrenia,¹⁵² but not in the amygdala.¹⁵³ This lack of change in the amygdala cell density expressing substance P receptor was consistent with mRNA expression.¹⁵³

OTHER MARKERS

Multiple other markers associated with inflammation that do not fit the categories mentioned above have also been measured in postmortem brains of schizophrenic patients to evaluate a potential link between neuroinflammation and schizophrenia. We identified 16 studies evaluating miscellaneous markers in postmortem brains in schizophrenia (Table 7).

ICAM-1 is a marker of neuroinflammation, associated with blood-brain barrier disruption. Thomas *et al.*¹⁵⁴ found no differences in ICAM-1 labeled cells in both the dorsolateral prefrontal cortex and anterior cingulate cortex of 15 schizophrenia patients of the Stanley Foundation Neuropathology Consortium compared to healthy controls.

Four studies investigated the NF-κB pathway in postmortem schizophrenic brains. Rao *et al.*⁷³ measured increases in both NF-κB p50 and p65 subunits mRNA expression in the BA10 of schizophrenia patients. A second study evaluating the prefrontal cortex of schizophrenics reported increased NF-κB1 and 2 mRNA expression.¹⁵⁵ However, 2 separate studies could not detect any differences in NF-κB2 expression in the frontal cortex¹⁵⁶ and NF-κB in the dorsolateral prefrontal cortex⁸⁶ between schizophrenics and healthy controls. Schnurri-2, a NF-κB site binding protein inhibiting downstream transcription, has been reported to be decreased in the prefrontal cortex of schizophrenia patients.¹⁵⁵

Microarray analyses followed by qPCR have proposed markers associated with the immune system or inflammatory response being associated with schizophrenia. One such marker, which was reported in four microarray analyses, is SERPINA3, a protease inhibitor that is involved in inflammatory processes and connective tissue turnover. In the dorsolateral prefrontal cortex, SERPINA3 mRNA expression was significantly higher in the brains of schizophrenics compared with healthy controls.⁸⁶ The same group confirmed this finding in a second cohort, finding increased SERPINA3 mRNA expression in the medial frontal gyrus in schizophrenia, whereas changes in IL-1RL1 expression were not detected.¹³⁹ Similar increases of SERPINA3 mRNA expression were reported in two other microarray studies in the frontal cortices of 55 (ref. 93) and 14 (ref. 157) schizophrenia patients and were confirmed by qPCR.

These two microarray studies also found elevated interferon-induced transmembrane protein (IFITM)1, 2 and 3, proteins involved in regulation of the immune response, mRNA expression in the prefrontal cortex in schizophrenia.^{93,157} A third study confirmed the increased IFITM3 mRNA expression in the prefrontal cortex.¹⁵⁸ Similar overexpression of IFITM1, 2 and 3 was observed by microarray and confirmed by qPCR in the hippocampus of schizophrenic patients.⁷⁷ A fifth study targeted IFITM1 and 2/3 expression in a separate cohort of prefrontal cortices of schizophrenia patients and reported an increase in both markers independent of antipsychotic use.¹⁵⁹

Other markers that either increased or decreased in microarrays include CD163 and S100a8 and 9 in the hippocampus,⁷⁷ CHI3L1 (ref. 157) and GBP1 (ref. 93) in the prefrontal cortex, TNFSF8, 10 and 13 (although 8 and 13 were not significant in PCR validation) in the dorsolateral prefrontal cortex,^{160,161} and TIMP1, TYROB and

Table 7. Other markers in postmortem schizophrenia brain

Author	Brain bank	n	Sex (m/f)	Age	Death from suicide	Brain region	Technique	Inflammatory markers	Results
Arion <i>et al.</i> ¹⁵⁷	UPCNMDBB	scz 14 ctr 14	scz 12/2 ctr 12/2	scz 43 ctr 42	scz 3	PFC (BA9)	PCR	SERPINA3, IFITM1, IFITM3, CHI3L1, HSPB1, MT2A	↑
Catts and Weickert ¹⁶¹	SMRIAC, NSWTRC	scz 72 ctr 71	scz 50/22 ctr 55/16	scz 47 ctr 48	scz 15	DLPFC*, OFC#	PCR	TNFSF13	↑*, ↔ #
Durrenberger <i>et al.</i> ⁹⁸	BBPDGU	scz 10 ctr 10	scz 5/5 ctr 5/5	scz 66 ctr 61	NA	TL (BA22)	PCR	TIMP1, TNFRSF1A, TYROBP	↓
Fillman <i>et al.</i> ⁸⁶	NSWTRC	scz 37 ctr 37	scz 24/13 ctr 26/9	scz 51 ctr 48	NA	DLPFC (BA46)	PCR	NFκB#, SERPINA3*, IL6ST#	↑* ↔ #
Fillman <i>et al.</i> ¹³⁹	SMRIAC	scz 35 ctr 35	scz 26/9 ctr 26/9	scz 43 ctr 44	scz 7	Middle frontal gyrus	PCR	SERPINA3*, IL-1 RL1#	↑* ↔ #
Harris <i>et al.</i> ¹³⁷	SMRIAC	scz 35 ctr 33	scz 26/9 ctr 25/8	scz 43 ctr 45	NA	BA10	ELISA	TIMP1	↔
Hwang <i>et al.</i> ⁷⁷	SNFC, SMRIAC	scz 33 ctr 34	scz 23/10 ctr 23/11	scz 44 ctr 46	NA	HPC	PCR	CD163, S100a8, S100a9, IFITM1, IFITM2, IFITM3	↑
Iwamoto <i>et al.</i> ¹⁵⁸	SFNC	scz 13 ctr 15	scz 8/5 ctr 9/6	scz 44 ctr 48	scz 4	PFC (BA10)	PCR	IFITM3	↑
Rao <i>et al.</i> ⁷³	HBTRC	scz 10 ctr 10	scz 6/4 ctr 7/3	scz 59 ctr 49	NA	FC (BA10)	PCR, WB	IL-1R#, NFκBp50*, NFκBp65*, iNOS#	↑* ↔ #
Saetre <i>et al.</i> ⁹³	SFNC, HBTRC, MBB	scz 55 ctr 55	NA	scz 59 ctr 55	NA	FC (BA8 and 9), superior frontal gyrus	PCR	IFITM2, IFITM3, SERPINA3, GPB1	↑
Schmitt <i>et al.</i> ⁹⁴	BBPDGU	scz 10 ctr 10	scz 5/5 ctr 8/2	scz 66 ctr 61	NA	TC (BA22)	PCR	LPL*, CFD*, PTGER4*, EDG3* ITGA1#, LCP1#, LTC4S#, MTHFD2#, SOD2#, CCR1#, IL1RAP#, IFI16#, IFNAR2#, CD84#, GPX#	↓* ↔ #
Shao and Vawter ¹⁶⁰	SMRIAC	scz 32 ctr 27	scz 23/9 ctr 23/6	scz 43 ctr 44	NA	DLPFC (BA46)	PCR	TNFSF8, TNFSF10	↔
Siegel <i>et al.</i> ¹⁵⁹	ACOME	scz 57 ctr 57	scz 42/15 ctr 42/15	scz 47 ctr 48	scz 16	PFC (BA9)	PCR, <i>in situ</i> hybridization	IFITM1, IFITM2/3	↑
Sun <i>et al.</i> ¹⁵⁶	SFNC	NA	NA	NA	NA	FC	PCR	NFκB2	↔
Thomas <i>et al.</i> ¹⁵⁴	SFNC	scz 15 ctr 15	scz 9/6 ctr 9/6	scz 45 ctr 48	scz 4	DLPFC (BA9,46), ACC (BA24)	IHC	ICAM-1	↔
Volk <i>et al.</i> ¹⁵⁵	ACOME	scz 62 ctr 62	scz 47/15 ctr 47/15	scz 48 ctr 49	scz 16	PFC (BA9)	PCR	NFκB1#, NFκB2#, Shn-2*	↓*↑#

Abbreviations: ACC, anterior cingulate cortex; ACOME, Allegheny County Office of the Medical Examiner; APOL, apolipoprotein L; BA, Brodmann area; BBPDGU, Brain Bank for Psychiatric Diseases at the Gottingen University; CCR, chemokine (c-c motif) receptor; CD, cluster of differentiation; CFD, complement factor D; CHI3L1, chitinase-3 like protein 1; ctr, control; DLPFC, dorsolateral prefrontal cortex; EDG3, endothelial differentiation, sphingolipid g-coupled-receptor; FC, frontal cortex; GPX, glutathione peroxidase; GPB, guanylate binding protein; HBTRC, Harvard Brain Tissue Resource Centre; HPC, hippocampus; HSPB, heat shock protein beta; ICAM, intercellular adhesion molecule; IFI, interferon gamma-inducible; IFITM, interferon-induced transmembrane; IFNAR, interferon (alpha, beta and omega) receptor; IHC, immunohistochemistry; IL1RAP, interleukin 1 receptor accessory protein; IL1RL, interleukin 1 receptor like; IL6ST, glycoprotein 130; ITGA, integrin alpha; iNOS, inducible nitric oxide; LCP, lymphocyte cytosolic protein; LPL, lipoprotein lipase; LTC4S, leukotriene C4 synthase; MBB, Maudsley Brain Bank; MT2A, metallothionein 2A; MTHFD, methylenetetrahydrofolate dehydrogenase; NA, not available; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; NSWTRC, New South Wales Tissue Resource Centre; OFC, orbitofrontal cortex; PCR, polymerase chain reaction; scz, schizophrenia; PFC, prefrontal cortex; PTGER, prostaglandin E receptor 4; SERPIN, serine protease inhibitor; SFNC, Stanley Foundation Neuropathology Consortium; Shn-2, Schnurri-2; SMRIAC, Stanley Medical Research Institute Array Collection; SOD, superoxide dismutase; TC, temporal cortex; TIMP, tissue inhibitor of metalloproteinases; TL, Temporal lobe; TNFSF, tumor necrosis factor superfamily; TYROBP, TYRO protein tyrosine kinase binding protein; UPCNMDBB, University of Pittsburgh's center for the neuroscience of mental disorder brain bank.

*, # indicate which variables results are representing.

TNFSRF1A in the temporal lobe.⁹⁸ However, unlike the decrease in TIMP1 mRNA expression measured in the temporal lobe, TIMP1 protein concentration, measured by enzyme-linked immunosorbent assay, was not changed in the prefrontal cortex in another study.¹³⁷ Schmitt *et al.* reported 6 out of 23 immune-related genes are downregulated in the superior temporal cortex in schizophrenia. The 23 immune-related genes include cytokines and microglial markers, discussed above, and other markers including LPL, CFD, PTGER4 and EDG3 being downregulated and ITGA1, LCP1, LTC4S, MTHFD2, CD84, GPX, IFI16 and SOD2 being unchanged.⁹⁴

DISCUSSION

Schizophrenia has been linked to neuroinflammation.^{8–10} Schizophrenic patients have been shown to have elevated cytokines in blood^{17,18} and elevated microglia activation in the brain as measured by PET analysis in some^{22,23} but not all^{25,26} reports. This paper systematically reviewed the literature covering neuroinflammatory analyses in postmortem brains from schizophrenic patients.

Multiple studies evaluating neuroinflammation in postmortem brain samples found evidence of neuroinflammation in schizophrenia. However, a definitive statement cannot be made on whether neuroinflammation is present in schizophrenic post-mortem brain samples due to the large number of null studies. For example, out of 33 studies evaluating GFAP, 21 studies did not find any effect of schizophrenia on GFAP expression, whereas 6 studies found a decrease in GFAP and 6 studies had elevated GFAP expression. Similarly, out of 34 studies that evaluated glial cell density, 25 studies found no effect of schizophrenia, whereas 7 studies found a decrease in glial cells and 2 studies found an increase. Variability is also observed for four microglial markers (HLA, CD11b, CD68 and calprotectin), where 11 studies had elevated expression of microglial markers, 8 studies found no differences and 3 found a decrease. SERPINA3, a protease inhibitor that is involved in inflammatory processes and connective tissue turnover, however, was elevated in the 4 studies, which have reported on its mRNA expression. IFITM, a viral restriction factor, was also reported elevated in four microarrays, and confirmed in one targeted study.

These discrepancies may be explained, at least partly, by the heterogeneity in study designs across studies. One of the heterogeneous variable across studies is brain region analyzed. For example, studies evaluating GFAP expression have analyzed 34 brain regions, including the hippocampus, prefrontal cortex, entorhinal cortex, orbitofrontal cortex and cingulate cortex among others. Whereas all five studies analyzing GFAP expression in the entorhinal cortex found no differences in schizophrenia, 4 of the 13 studies evaluating GFAP expression in the frontal cortex, prefrontal cortex or dorsolateral prefrontal cortex (BA9, 10 or 46) identified differences between schizophrenia and healthy controls. However, classification of the frontal cortices varied between studies and may explain differing results. Moreover, four out of six studies examining the cingulate cortex, subgenual cingulate cortex or anterior cingulate cortex found significant changes in GFAP in schizophrenia. It is possible that certain brain regions, such as the cingulate cortex, are more susceptible to change in schizophrenia compared to other regions such as the entorhinal cortex. Nevertheless, despite more studies pointing to a decrease in GFAP expression in the cingulate cortex in schizophrenia, not all studies show decreases despite evaluating the same brain region and marker.^{53,58}

Consideration of the cortical layer in which the markers are measured may be needed in order to tease out the differences across studies. Many studies found layer-specific effects in various brain regions and markers. For example, in two studies, GFAP expression was increased solely in layer V of the dorsolateral

prefrontal cortex⁷⁰ and layer I in subgenual cingulate cortex.⁶⁷ This could explain differences across studies measuring GFAP in the whole prefrontal cortex mentioned above. Similarly, layer-specific effects of schizophrenia on glial cell density measured by cresyl violet were observed in several studies evaluating the motor cortex (layer III), planum temporale (layer IV), cingulate cortex (layer IV) and dorsolateral prefrontal cortex (layer V).

Differences in methodological approaches also warrant consideration when evaluating the results of the studies mentioned above. Stereological analysis, an unbiased cell counting method, was applied to approximately half of the studies measuring glial cells. Only one study utilizing stereology measured differences in glial cell density, whereas seven studies using other methods reported differences. However, the use of stereology is not always clear in the methods section and therefore the results above should be considered with caution. Similarly, double labeling could be utilized to detect different subtypes of cells. However, few studies in this review utilized double labeling, which should be considered when no differences in cell densities are detected. Thus, the lack of changes in cell densities may not reflect changes in subtypes of cells.

Another variable that may contribute to the heterogeneous results is the stage of the disorder. By separating paranoid schizophrenia from residual schizophrenia, differences in S100b-positive cells were observed.⁷⁹ Microglia are also elevated in paranoid schizophrenia, where HLA-DR-positive cell density is higher in paranoid schizophrenia compared with residual schizophrenia.⁸⁸ Moreover, differences in gliosis score are seen between early onset and late onset schizophrenia.¹³⁵ Similarly, the three patients with microgliosis in the study by Bayer *et al.*⁸⁵ were all defined to have late onset schizophrenia.

Suicide is common in schizophrenia. This is important to consider as postmortem brains from suicide victims may present elevated pro-inflammatory cytokines.^{162,163} This is in agreement with Steiner and colleagues where the two schizophrenia patients that committed suicide had the highest HLA-DR-positive cell density.⁹¹ When accounting for suicide victims, the same group found no differences between diagnosis groups. They did, however, find a relation between suicide and HLA-DR-positive cells.⁹² Similarly, GFAP cell density is elevated in the dorsolateral prefrontal cortex of suicide victims compared with non-suicide schizophrenic patients.⁵⁵ This effect on GFAP, in the dorsolateral prefrontal cortex of suicide victims, however, was not seen in another study measuring GFAP by western blot.⁶⁵ No effect of suicide was also observed for ICAM-1 expression.¹⁵⁴ This is also an important consideration for control group selection. Tooney *et al.*¹⁵² found an effect of schizophrenia on neurokinin 1 receptor compared with a control group that contained suicide victims, which may potentially confound the results. Although a few studies considered the effect of suicide on their measurements, many studies do not report this data or include it in their statistical analysis, making it a limitation and should be considered in future studies.

Several other confounding factors have been associated with potential effects on neuroinflammatory markers in schizophrenia in postmortem brains. Antipsychotics have been associated with modulation of inflammation.¹⁶⁴ Typical antipsychotics generally reduce pro-inflammatory markers while atypical antipsychotics generally increase them.^{164,165} In our systematic review, antipsychotics were reported to raise GFAP,^{53,71,74} substance P¹⁴⁸ and HLA.⁵³ No effect of medication, however, was seen on IL-1 β .¹³⁶ This is important to note, as not all studies measured antipsychotic levels at time of death or corrected for this potential confounder. Moreover, even when measured, separation of typical and atypical antipsychotics was not considered in the statistical analysis. Also, control subjects would not have been exposed to antipsychotic medication, potentially creating a confounder between controls and the experimental group. Similarly, age is

positively correlated to the expression of GFAP,⁶⁶ S100⁵⁸ and substance P receptor binding.¹⁵¹ Lifestyle choices, such as smoking and alcohol abuse, may also contribute to neuroinflammation. In one study, decreases in MHC I observed in the dorsolateral prefrontal cortex of non-smoking schizophrenia patients were no longer apparent in the smoking population.¹⁰⁰ Interestingly, lifestyle choices and antipsychotic use are also risk factors for the development of type II diabetes,¹⁶⁶ which is more prevalent in schizophrenia¹⁶⁷ and has been associated with neuroinflammation.^{168,169} Although not reported in the studies in this review, it would be of interest for future studies to investigate a potential link between diabetes in schizophrenia and neuroinflammation.

The source of the brains also needs consideration. Several brain banks produced multiple studies utilizing several different brain regions from the same brains. Brain banks may have different diagnosis methods, inclusion and exclusion criteria, storage, and demographics among many other variables. Thus, it is possible that the results may be biased by where the brains samples used were provided from. For example, the 33 studies on GFAP reported in this paper were generated from brains from 15 separate brain banks. Of those 33 studies, 6 studies reported a decrease in GFAP. Of those 6 studies, 2 studies utilized the Stanley Foundation Neuropathology Consortium whereas 3 other studies used the Corsellis Brain Collection.

Despite the heterogeneity across studies, the expression of both SERPINA3 and IFITM was repeatedly found to be increased in microarray studies. SERPINA3, a member of the serine protein inhibitor family, is an acute-phase protein which increases during inflammatory episodes¹⁷⁰ and is expressed in reactive astrocytes.¹⁷¹ SERPINA3 has previously been linked with decreased age of onset of Alzheimer's symptoms.¹⁷² Moreover, SERPINA3 expression is correlated with GFAP positive cells in Alzheimer's disease.¹⁷³ Patients with multiple sclerosis have elevated SERPINA3 CFS concentration.¹⁷⁴ In depression, no association was reported between blood levels of SERPINA3 and symptoms.¹⁷⁵ IFITM, on the other hand, is an immune-related protein involved in viral replication. In animal models of inflammation, IFITM1 is increased in the cortex of mice lacking the NF- κ B site binding protein Schnurri-2.¹⁷⁶ Similarly, IFITM1 and 3 expression is upregulated in the hippocampus following centrally administered lipopolysaccharide injection,¹⁷⁷ suggesting its involvement in neuroinflammatory processes.

In conclusion, although the majority of studies note a lack of change in neuroinflammatory markers in postmortem brain samples of patients with schizophrenia, there are still multiple studies indicating either increases or decreases in neuroinflammatory markers. Although ~70% of studies evaluating astrocytes or glial cells in schizophrenia found no change, there were still ~30% of studies showing either an increase or decrease in astrocytic markers and glial cell density. The changes in microglial markers in schizophrenia is more variable across studies, with ~45% of studies showing an increase and 40% of studies showing no change. Similarly, pro-inflammatory cytokine concentration in the postmortem schizophrenia brain is also variable across studies, with studies showing both elevated and decreased cytokine levels in schizophrenia. The cause of this heterogeneity in results is not clear at the moment, but may be due to several factors including brain region measured, stage of disorder, source of the brain and medication. Despite this heterogeneity, microarray analyses have consistently indicated markers such as SERPINA3 and IFITM to be elevated in schizophrenia. Future studies should consider these potential sources of heterogeneity when measuring neuroinflammatory markers in postmortem brain samples of schizophrenia patients.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

MOT holds a studentship from the Natural Sciences and Engineering Research Council of Canada (PGSD-442373-2013). RPB acknowledges funding from the Canadian Institutes of Health Research (#303157) and holds a Canada Research Chair in Brain Lipid Metabolism. The authors would also acknowledge Dr. J.L. Sievenpiper for the helpful discussion on systematic reviews.

REFERENCES

- 1 Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, 'just the facts' what we know in 2008. 2. Epidemiology and etiology. *Schizophr Res* 2008; **102**: 1–18.
- 2 van Os J, Kapur S. Schizophrenia. *Lancet* 2009; **374**: 635–645.
- 3 Insel TR. Rethinking schizophrenia. *Nature* 2010; **468**: 187–193.
- 4 Roussos P, Haroutunian V. Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities. *Front Cell Neurosci* 2014; **8**: 5.
- 5 Karoutzou G, Emrich HM, Dietrich DE. The myelin-pathogenesis puzzle in schizophrenia: a literature review. *Mol Psychiatry* 2008; **13**: 245–260.
- 6 Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. *Schizophr Bull* 2009; **35**: 509–527.
- 7 Abi-Dargham A. Schizophrenia: overview and dopamine dysfunction. *J Clin Psychiatry* 2014; **75**: e31.
- 8 Leza JC, Garcia-Bueno B, Bioque M, Arango C, Parellada M, Do K et al. Inflammation in schizophrenia: a question of balance. *Neurosci Biobehav Rev* 2015; **55**: 612–626.
- 9 Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. *J Neuroinflammation* 2013; **10**: 43.
- 10 Reus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. *Neuroscience* 2015; **300**: 141–154.
- 11 Müller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. *Front Neurosci* 2015; **9**: 372.
- 12 Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. *Immunol Rev* 2006; **213**: 48–65.
- 13 Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. *J Neuroinflammation* 2014; **11**: 98.
- 14 Rapoport SI. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. *ACS Chem Neurosci* 2014; **5**: 459–467.
- 15 van Neerven S, Nemes A, Imholz P, Regen T, Denecke B, Johann S et al. Inflammatory cytokine release of astrocytes in vitro is reduced by all-trans retinoic acid. *J Neuroimmunol* 2010; **229**: 169–179.
- 16 Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL et al. Neuroinflammation in Alzheimer's disease. *Lancet Neurol* 2015; **14**: 388–405.
- 17 Potvin S, Stip E, Seppehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. *Biol Psychiatry* 2008; **63**: 801–808.
- 18 Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. *Biol Psychiatry* 2011; **70**: 663–671.
- 19 Barme M, Wood J, Chowdari K, Watson AM, Celik C, Mansour H et al. Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure. *Schizophr Bull* 2012; **38**: 1149–1154.
- 20 Yue WH, Wang HF, Sun LD, Tang FL, Liu ZH, Zhang HX et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. *Nat Genet* 2011; **43**: 1228–1231.
- 21 Pasternak O, Kubicki M, Shenton ME. *In vivo* imaging of neuroinflammation in schizophrenia. *Schizophr Res* 2015; **41**: 85–93.
- 22 van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitmaker A, Caspers E et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. *Biol Psychiatry* 2008; **64**: 820–822.
- 23 Doorduyn J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. *J Nucl Med* 2009; **50**: 1801–1807.
- 24 Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study. *Am J Psychiatry* 2016; **173**: 44–52.
- 25 Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an *in vivo* PET study with [18 F]-FEPPA. *Schizophr Bull* 2015; **41**: 85–93.
- 26 Takano A, Arakawa R, Ito H, Tateno A, Takahashi H, Matsumoto R et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. *Int J Neuropsychopharmacol* 2010; **13**: 943–950.

- 27 Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K *et al*. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. *Am J Psychiatry* 2002; **159**: 1029–1034.
- 28 Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. *Schizophr Res* 2007; **90**: 179–185.
- 29 Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2010; **71**: 520–527.
- 30 Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. *Biol Psychiatry* 2005; **57**: 1594–1596.
- 31 Nitta M, Kishimoto T, Muller N, Weiser M, Davidson M, Kane JM *et al*. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. *Schizophr Bull* 2013; **39**: 1230–1241.
- 32 Trépanier MO, Hopperton KE, Orr SK, Bazinet RP. N-3 polyunsaturated fatty acids in animal models with neuroinflammation: an update. *Eur J Pharmacol* 2016; e-pub ahead of print.
- 33 Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? *Br J Clin Pharmacol* 2013; **75**: 645–662.
- 34 Emsley R, Chiliza B, Asmal L, du Plessis S, Phahladira L, van Niekerk E *et al*. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. *Schizophr Res* 2014; **158**: 230–235.
- 35 Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM *et al*. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. *Arch Gen Psychiatry* 2010; **67**: 146–154.
- 36 Buntinx M, Moreels M, Vandenabeele F, Lambrichts I, Raus J, Steels P *et al*. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. *J Neurosci Res* 2004; **76**: 834–845.
- 37 Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. *Nature* 2006; **440**: 1054–1059.
- 38 Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. *Front Neuroendocrinol* 2012; **33**: 315–327.
- 39 Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. *Science* 2003; **302**: 1760–1765.
- 40 Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. *Glia* 1999; **28**: 114–127.
- 41 Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. *Schizophr Res* 2015; **161**: 102–112.
- 42 Tooyama I, Kimura H, Akiyama H, McGeer PL. Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease. *Brain Res* 1990; **523**: 273–280.
- 43 Roberts GW, Colter N, Lofthouse R, Bogerts B, Zech M, Crow TJ. Gliosis in schizophrenia: a survey. *Biol Psychiatry* 1986; **21**: 1043–1050.
- 44 Roberts GW, Colter N, Lofthouse R, Johnstone EC, Crow TJ. Is there gliosis in schizophrenia? Investigation of the temporal lobe. *Biol Psychiatry* 1987; **22**: 1459–1468.
- 45 Arnold SE, Franz BR, Trojanowski JQ, Moberg PJ, Gur RE. Glial fibrillary acidic protein-immunoreactive astrogliosis in elderly patients with schizophrenia and dementia. *Acta Neuropathol* 1996; **91**: 269–277.
- 46 Arnold SE, Trojanowski JQ, Gur RE, Blackwell P, Han LY, Choi C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. *Arch Gen Psychiatry* 1998; **55**: 225–232.
- 47 Pantazopoulos H, Woo TUW, Lim MP, Lange N, Berretta S. Extracellular matrix-glia abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. *Arch Gen Psychiatry* 2010; **67**: 155–166.
- 48 Altshuler LL, Abulseoud OA, Folland-Ross L, Bartzokis G, Chang S, Mintz J *et al*. Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. *Bipolar Disord* 2010; **12**: 541–549.
- 49 Falkai P, Honer WG, David S, Bogerts B, Majtenyi C, Bayer TA. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. *Neuropathol Appl Neurobiol* 1999; **25**: 48–53.
- 50 Falke E, Han LY, Arnold SE. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. *Psychiatry Res* 2000; **93**: 103–110.
- 51 Stevens CD, Altshuler LL, Bogerts B, Falkai P. Quantitative study of gliosis in schizophrenia and Huntington's chorea. *Biol Psychiatry* 1988; **24**: 697–700.
- 52 Williams MR, Marsh R, Macdonald CD, Jain J, Pearce RK, Hirsch SR *et al*. Neuropathological changes in the nucleus basalis in schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2013; **263**: 485–495.
- 53 Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. *J Neuropathol Exp Neurol* 2000; **59**: 137–150.
- 54 Damadzic R, Bigelow LB, Krimer LS, Goldenson DA, Saunders RC, Kleinman JE *et al*. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrogliosis. [References]. *Brain Res Bull* 2001; **55**: 611–618.
- 55 Hercher C, Chopra V, Beasley CL. Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder. *J Psychiatry Neurosci* 2014; **39**: 376–385.
- 56 Webster MJ, Knable MB, Johnston-Wilson N, Nagata K, Inagaki M, Yolken RH. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. *Brain Behav Immun* 2001; **15**: 388–400.
- 57 Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB *et al*. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. *Lancet* 2003; **362**: 798–805.
- 58 Katsel P, Byne W, Roussos P, Tan W, Siever L, Haroutunian V. Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. *Neuropsychopharmacology* 2011; **36**: 1171–1177.
- 59 Beasley CL, Dwork AJ, Rosoklija G, Mann JJ, Mancevski B, Jakovski Z *et al*. Metabolic abnormalities in fronto-striatal-thalamic white matter tracts in schizophrenia. *Schizophr Res* 2009; **109**: 159–166.
- 60 Fatemi SH, Laurence JA, Araghi-Niknam M, Stary JM, Schulz SC, Lee S *et al*. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. *Schizophr Res* 2004; **69**: 317–323.
- 61 Karson CN, Casanova MF, Kleinman JE, Griffin WST. Choline acetyltransferase in schizophrenia. *Am J Psychiatry* 1993; **150**: 454–459.
- 62 Dean B, Gray L, Scarr E. Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. *Aust N Z J Psychiatry* 2006; **40**: 217–224.
- 63 Karson CN, Mrak RE, Schluterman KO, Sturmer WQ, Sheng JG, Griffin WS. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. *Mol Psychiatry* 1999; **4**: 39–45.
- 64 Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. *Proc Natl Acad Sci USA* 1996; **93**: 14182–14187.
- 65 Feresten AH, Barakauskas V, Ypsilanti A, Barr AM, Beasley CL. Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness. *Schizophr Res* 2013; **150**: 252–257.
- 66 Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. *Schizophr Res* 2008; **103**: 71–82.
- 67 Williams MR, Hampton T, Pearce RK, Hirsch SR, Ansorge O, Thom M *et al*. Astrocyte decrease in the subgenual cingulate and callosal genu in schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2013; **263**: 41–52.
- 68 Williams M, Pearce RK, Hirsch SR, Ansorge O, Thom M, Maier M. Fibrillary astrocytes are decreased in the subgenual cingulate in schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2014; **264**: 357–362.
- 69 Williams MR, Galvin K, O'Sullivan B, MacDonald CD, Ching EW, Turkheimer F *et al*. Neuropathological changes in the substantia nigra in schizophrenia but not depression. *Eur Arch Psychiatry Clin Neurosci* 2014; **264**: 285–296.
- 70 Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, Meltzer H, Overholser J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. *Schizophr Res* 2002; **57**: 127–138.
- 71 Toro CT, Hallak JE, Dunham JS, Deakin JF. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. *Neurosci Lett* 2006; **404**: 276–281.
- 72 Markova E, Markov I, Revishchin A, Okhotin V, Sulimov G. 3-D Golgi and image analysis of the olfactory tubercle in schizophrenia. *Anal Quant Cytol Histol* 2000; **22**: 178–182.
- 73 Rao JS, Kim HW, Harry GJ, Rapoport SI, Reese EA. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. *Schizophr Res* 2013; **147**: 24–31.
- 74 Barley K, Dracheva S, Byne W. Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. *Schizophr Res* 2009; **112**: 54–64.

- 75 Catts VS, Wong J, Fillman SG, Fung SJ, Shannon Weickert C. Increased expression of astrocyte markers in schizophrenia: association with neuroinflammation. *Aust N Z J Psychiatry* 2014; **48**: 722–734.
- 76 Webster MJ, O'Grady J, Kleinman JE, Weickert CS. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. *Neuroscience* 2005; **133**: 453–461.
- 77 Hwang Y, Kim J, Shin JY, Kim JI, Seo JS, Webster MJ et al. Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. *Transl Psychiatry* 2013; **3**: 1–9.
- 78 Steiner J, Schmitt A, Schroeter ML, Bogerts B, Falkai P, Turck CW et al. S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. *Eur Arch Psychiatry Clin Neurosci* 2014; **264**: 311–316.
- 79 Steiner J, Bernstein HG, Bielau H, Farkas N, Winter J, Dobrowolny H et al. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. *J Psychiatr Res* 2008; **42**: 868–876.
- 80 Casanova MF, Stevens JR, Kleinman JE. Astrocytosis in the molecular layer of the dentate gyrus: a study in Alzheimer's disease and schizophrenia. *Psychiatry Res* 1990; **35**: 149–166.
- 81 Schmitt A, Steyskal C, Bernstein HG, Schneider-Axmann T, Parlapani E, Schaeffer EL et al. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. *Acta Neuropathol* 2009; **117**: 395–407.
- 82 Pakkenberg B. Pronounced reduction of total neuron number in mediadorsal thalamic nucleus and nucleus accumbens in schizophrenics. *Arch Gen Psychiatry* 1990; **47**: 1023–1028.
- 83 Kolomeets NS, Uranova N. Ultrastructural abnormalities of astrocytes in the hippocampus in schizophrenia and duration of illness: a postmortem morphometric study. *World J Biol Psychiatry* 2010; **11**: 282–292.
- 84 Uranova NA, Zimina IS, Vikhрева OV, Krukov NO, Rachmanova VI, Orlovskaya DD. Ultrastructural damage of capillaries in the neocortex in schizophrenia. *World J Biol Psychiatry* 2010; **11**: 567–578.
- 85 Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. *Neurosci Lett* 1999; **271**: 126–128.
- 86 Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. *Mol Psychiatry* 2013; **18**: 206–214.
- 87 Wierzbica-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. *Folia Neuropathol* 2005; **43**: 81–89.
- 88 Busse S, Busse M, Schiltz K, Bielau H, Gos T, Brisch R et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? *Brain Behav Immun* 2012; **26**: 1273–1279.
- 89 Wierzbica-Bobrowicz T, Lewandowska E, Kosno-Kruszewska E, Lechowicz W, Pasennik E, Schmidt-Sidor B. Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenics. *Folia Neuropathol* 2004; **42**: 157–165.
- 90 Foster R, Kandaneeratchi A, Beasley C, Williams B, Khan N, Fagerhol MK et al. Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an inflammatory process? *Eur J Neurosci* 2006; **24**: 3561–3566.
- 91 Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. *Acta Neuropathol* 2006; **112**: 305–316.
- 92 Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. *J Psychiatr Res* 2008; **42**: 151–157.
- 93 Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. *BMC Psychiatry* 2007; **7**: 46.
- 94 Schmitt A, Leonardi-Essmann F, Durrenberger PF, Parlapani E, Schneider-Axmann T, Spanagel R et al. Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. *World J Biol Psychiatry* 2011; **12**: 201–215.
- 95 Comte I, Kotagiri P, Szele FG. Regional differences in human ependymal and subventricular zone cytoarchitecture are unchanged in neuropsychiatric disease. *Dev Neurosci* 2012; **34**: 299–309.
- 96 Nakatani N, Hattori E, Ohnishi T, Dean B, Iwayama Y, Matsumoto I et al. Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. *Hum Mol Genet* 2006; **15**: 1949–1962.
- 97 Connor CM, Guo Y, Akbarian S. Cingulate white matter neurons in schizophrenia and bipolar disorder. *Biol Psychiatry* 2009; **66**: 486–493.
- 98 Durrenberger PF, Fernando FS, Kashfi SN, Bonnert TP, Seilhean D, Nait-Oumesmar B et al. Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. *J Neural Transm (Vienna)* 2015; **122**: 1055–1068.
- 99 Gos T, Myint AM, Schiltz K, Meyer-Lotz G, Dobrowolny H, Busse S et al. Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients. *Brain Behav Immun* 2014; **41**: 59–64.
- 100 Kano S, Nwulia E, Niwa M, Chen Y, Sawa A, Cascella N. Altered MHC class I expression in dorsolateral prefrontal cortex of nonsmoker patients with schizophrenia. *Neurosci Res* 2011; **71**: 289–293.
- 101 Sinkus ML, Adams CE, Logel J, Freedman R, Leonard S. Expression of immune genes on chromosome 6p21.3-22.1 in schizophrenia. *Brain Behav Immunity* 2013; **32**: 51–62.
- 102 Stevens JR. Neuropathology of schizophrenia. *Arch Gen Psychiatry* 1982; **39**: 1131–1139.
- 103 Bruton CJ, Crow TJ, Frith CD, Johnstone EC, Owens DG, Roberts GW. Schizophrenia and the brain: a prospective clinico-neuropathological study. *Psychol Med* 1990; **20**: 285–304.
- 104 Falkai P, Bogerts B. Cell loss in the hippocampus of schizophrenics. *Eur Arch Psychiatry Neurol Sci* 1986; **236**: 154–161.
- 105 Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. *Am J Psychiatry* 2004; **161**: 882–888.
- 106 Brauch RA, Adnan El-Masri M, Parker JC Jr., El-Mallakh RS. Glial cell number and neuron/glial cell ratios in postmortem brains of bipolar individuals. *J Affect Disord* 2006; **91**: 87–90.
- 107 Beasley CL, Honavar M, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the superior temporal white matter in schizophrenia, major depressive disorder and bipolar disorder. *Schizophr Res* 2009; **115**: 156–162.
- 108 Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. *Cereb Cortex* 2002; **12**: 386–394.
- 109 Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. *Arch Gen Psychiatry* 2001; **58**: 545–553.
- 110 Benes FM, Davidson J, Bird ED. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. *Arch Gen Psychiatry* 1986; **43**: 31–35.
- 111 Kurumaji A, Wakai T, Toru M. Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. *J Neural Transm (Vienna)* 1997; **104**: 1361–1370.
- 112 Bezchlibnyk YB, Sun X, Wang JF, MacQueen GM, McEwen BS, Young LT. Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder. *J Psychiatry Neurosci* 2007; **32**: 203–210.
- 113 Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. *Arch Gen Psychiatry* 1995; **52**: 805–818; discussion 819–820.
- 114 Selemon LD, Mrzljak J, Kleinman JE, Herman MM, Goldman-Rakic PS. Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca's area 44 and area 9. *Arch Gen Psychiatry* 2003; **60**: 69–77.
- 115 Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. *Arch Gen Psychiatry* 1998; **55**: 215–224.
- 116 Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. *J Comp Neurol* 1998; **392**: 402–412.
- 117 Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. *Proc Natl Acad Sci USA* 1998; **95**: 13290–13295.
- 118 Falkai P, Bogerts B, Rozumek M. Limbic pathology in schizophrenia: the entorhinal region—a morphometric study. *Biol Psychiatry* 1988; **24**: 515–521.
- 119 Di Rosa E, Crow TJ, Walker MA, Black G, Chance SA. Reduced neuron density, enlarged minicolumn spacing and altered ageing effects in fusiform cortex in schizophrenia. *Psychiatry Res* 2009; **166**: 102–115.
- 120 Cullen TJ, Walker MA, Eastwood SL, Esiri MM, Harrison PJ, Crow TJ. Anomalies of asymmetry of pyramidal cell density and structure in dorsolateral prefrontal cortex in schizophrenia. *Br J Psychiatry* 2006; **188**: 26–31.
- 121 Chana G, Landau S, Everall I, Cotter D. Glial cell number and nuclear size in the mediadorsal thalamic nucleus (MDNT) in schizophrenia. *Schizophr Res* 2008; **102**: 344–345.
- 122 Cotter D, Mackay D, Frangou S, Hudson L, Landau S. Cell density and cortical thickness in Heschl's gyrus in schizophrenia, major depression and bipolar disorder. *Br J Psychiatry* 2004; **185**: 258–259.
- 123 Benes FM, Vincent SL, Todtenkopf M. The density of pyramidal and non-pyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. *Biol Psychiatry* 2001; **50**: 395–406.
- 124 Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder,

- bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. *Biol Psychiatry* 2003; **53**: 1086–1098.
- 125 Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. *Arch Gen Psychiatry* 1991; **48**: 996–1001.
- 126 Pennington K, Dicker P, Hudson L, Cotter DR. Evidence for reduced neuronal somal size within the insular cortex in schizophrenia, but not in affective disorders. *Schizophr Res* 2008; **106**: 164–171.
- 127 Cotter D, Hudson L, Landau S. Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. *Bipolar Disord* 2005; **7**: 358–369.
- 128 Jonsson SA, Luts A, Guldborg-Kjaer N, Brun A. Hippocampal pyramidal cell disarray correlates negatively to cell number: implications for the pathogenesis of schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 1997; **247**: 120–127.
- 129 Beasley CL, Chana G, Honavar M, Landau S, Everall IP, Cotter D. Evidence for altered neuronal organisation within the planum temporale in major psychiatric disorders. *Schizophr Res* 2005; **73**: 69–78.
- 130 Bogerts B, Hantsch J, Herzer M. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. *Biol Psychiatry* 1983; **18**: 951–969.
- 131 Selemon LD, Begovic A. Stereologic analysis of the lateral geniculate nucleus of the thalamus in normal and schizophrenic subjects. *Psychiatry Res* 2007; **151**: 1–10.
- 132 Hoistad M, Heinsen H, Wicinski B, Schmitz C, Hof PR. Stereological assessment of the dorsal anterior cingulate cortex in schizophrenia: absence of changes in neuronal and glial densities. *Neuropathol Appl Neurobiol* 2013; **39**: 348–361.
- 133 Beckmann H, Lauer M. The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics. *Psychiatry Res* 1997; **68**: 99–109.
- 134 Crow TJ, Ball J, Bloom SR, Brown R, Bruton CJ, Colter N *et al*. Schizophrenia as an anomaly of development of cerebral asymmetry. A postmortem study and a proposal concerning the genetic basis of the disease. *Arch Gen Psychiatry* 1989; **46**: 1145–1150.
- 135 Nasrallah HA, McCalley-Whitters M, Bigelow LB, Rauscher FP. A histological study of the corpus callosum in chronic schizophrenia. *Psychiatry Res* 1983; **8**: 251–260.
- 136 Toyooka K, Watanabe Y, Iritani S, Shimizu E, Iyo M, Nakamura R *et al*. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. *Neurosci Res* 2003; **46**: 299–307.
- 137 Harris LW, Pietsch S, Cheng TM, Schwarz E, Guest PC, Bahn S. Comparison of peripheral and central schizophrenia biomarker profiles. *PLoS ONE* 2012; **7**: e46368.
- 138 Dean B, Gibbons AS, Tawadros N, Brooks L, Everall IP, Scarr E. Different changes in cortical tumor necrosis factor- α -related pathways in schizophrenia and mood disorders. *Mol Psychiatry* 2013; **18**: 767–773.
- 139 Fillman SG, Sinclair D, Fung SJ, Webster MJ, Shannon Weickert C. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. *Transl Psychiatry* 2014; **4**: e365.
- 140 Maida ME, Hurley SD, Daeschner JA, Moore AH, O'Banion MK. Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. *Brain Res* 2006; **1103**: 164–172.
- 141 Tang B, Capitao C, Dean B, Thomas EA. Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. *Psychiatry Res* 2012; **196**: 201–206.
- 142 Yokota O, Terada S, Ishihara T, Nakashima H, Kugo A, Ujike H *et al*. Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2004; **28**: 715–721.
- 143 Carletti R, Corsi M, Melotto S, Caberlotto L. Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. *Eur J Neurosci* 2005; **21**: 1712–1718.
- 144 Harrington KA, Augood SJ, Faull RL, McKenna PJ, Emson PC. Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: a quantitative cellular in situ hybridisation study. *Brain Res Mol Brain Res* 1995; **33**: 333–342.
- 145 Iadarola MJ, Ofri D, Kleinman JE. Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patients. *Life Sci* 1991; **48**: 1919–1930.
- 146 Kleinman JE, Hong J, Iadarola M, Govoni S, Gillin CJ. Neuropeptides in human brain—postmortem studies. *Prog Neuropsychopharmacol Biol Psychiatry* 1985; **9**: 91–95.
- 147 Zech M, Bogerts B. Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study. *Acta Neuropathol* 1985; **68**: 32–38.
- 148 Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H *et al*. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. *Acta Psychiatr Scand* 1988; **78**: 121–137.
- 149 Roberts GW, Ferrier IN, Lee Y, Crow TJ, Johnstone EC, Owens DG *et al*. Peptides, the limbic lobe and schizophrenia. *Brain Res* 1983; **288**: 199–211.
- 150 Rioux L, Nissanov J, Joyce JN. Increased number of [125I] BH-substance p receptors in schizophrenia. *Prog Neuro-psychopharmacol Biol Psychiatry* 1998; **22**: 1295–1299.
- 151 Burnet PW, Harrison PJ. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. *Biol Psychiatry* 2000; **47**: 80–83.
- 152 Tooney PA, Crawter VC, Chahl LA. Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia. *Biol Psychiatry* 2001; **49**: 523–527.
- 153 Weidenhofer J, Yip J, Zavitsanou K, Huang XF, Chahl LA, Tooney PA. Immunohistochemical localisation of the NK1 receptor in the human amygdala: preliminary investigation in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2006; **30**: 1313–1321.
- 154 Thomas AJ, Davis S, Ferrier IN, Kalaria RN, O'Brien JT. Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. *Biol Psychiatry* 2004; **55**: 652–655.
- 155 Volk DW, Chitrapu A, Edelson JR, Roman KM, Moroco AE, Lewis DA. Molecular mechanisms and timing of cortical immune activation in schizophrenia. *Am J Psychiatry* 2015; **172**: 1112–1121.
- 156 Sun Y, Zhang L, Johnston NL, Torrey EF, Yolken RH. Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder. *Br J Psychiatry Suppl* 2001; **41**: s137–s141.
- 157 Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. *Biol Psychiatry* 2007; **62**: 711–721.
- 158 Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. *Mol Psychiatry* 2004; **9**: 406–416.
- 159 Siegel BJ, Sengupta EJ, Edelson JR, Lewis DA, Volk DW. Elevated viral restriction factor levels in cortical blood vessels in schizophrenia. *Biol Psychiatry* 2014; **76**: 160–167.
- 160 Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. *Biol Psychiatry* 2008; **64**: 89–97.
- 161 Catts VS, Weickert CS. Gene expression analysis implicates a death receptor pathway in schizophrenia pathology. *PLoS ONE* 2012; **7**: e35511.
- 162 Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC *et al*. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. *J Psychiatr Res* 2012; **46**: 57–63.
- 163 Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K *et al*. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. *Acta Psychiatr Scand* 2008; **117**: 198–206.
- 164 Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2014; **48**: 277–286.
- 165 Drzyzga L, Obuchowicz E, Marciniowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. *Brain Behav Immun* 2006; **20**: 532–545.
- 166 Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. *Front Neurosci* 2015; **9**: 297.
- 167 Suvisaari J, Perala J, Saarni SI, Harkanen T, Pirkola S, Joukamaa M *et al*. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. *Eur Arch Psychiatry Clin Neurosci* 2008; **258**: 129–136.
- 168 Purkayastha S, Cai D. Neuroinflammatory basis of metabolic syndrome. *Mol Metab* 2013; **2**: 356–363.
- 169 van Dijk G, van Heijningen S, Reijne AC, Nyakas C, van der Zee EA, Eisel UL. Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. *Front Neurosci* 2015; **9**: 173.
- 170 Kalsheker NA. Alpha 1-antichymotrypsin. *Int J Biochem Cell Biol* 1996; **28**: 961–964.
- 171 Gopalan SM, Wilczynska KM, Konik BS, Bryan L, Kordula T. Astrocyte-specific expression of the alpha1-antichymotrypsin and glial fibrillary acidic protein genes requires activator protein-1. *J Biol Chem* 2006; **281**: 1956–1963.
- 172 Kamboh MI, Minster RL, Kenney M, Ozturk A, Desai PP, Kammerer CM *et al*. Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer's disease. *Neurobiol Aging* 2006; **27**: 1435–1439.
- 173 Licastro F, Mallory M, Hansen LA, Masliah E. Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. *J Neuroimmunol* 1998; **88**: 105–110.

- 174 Ottervald J, Franzen B, Nilsson K, Andersson LI, Khademi M, Eriksson B *et al*. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. *J Proteomics* 2010; **73**: 1117–1132.
- 175 Zalli A, Jovanova O, Hoogendijk WJ, Tiemeier H, Carvalho LA. Low-grade inflammation predicts persistence of depressive symptoms. *Psychopharmacology* 2015.
- 176 Takao K, Kobayashi K, Hagihara H, Ohira K, Shoji H, Hattori S *et al*. Deficiency of schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia. *Neuropsychopharmacology* 2013; **38**: 1409–1425.
- 177 Bonow RH, Aid S, Zhang Y, Becker KG, Bosetti F. The brain expression of genes involved in inflammatory response, the ribosome, and learning and memory is

altered by centrally injected lipopolysaccharide in mice. *Pharmacogenomics J* 2009; **9**: 116–126.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Supplementary Information accompanies the paper on the Molecular Psychiatry website (<http://www.nature.com/mp>)